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ABSTRACT 
The growth hormone (GH) family peptides such as GH, prolactin (PRL), and 
somatolactin (SL) regulate a wide array of physiological actions including but not limited to 
growth, metabolism, osmoregulation, and lipolysis. These actions are regulated by many factors 
both internal and external. I used rainbow trout (Oncorhynchus mykiss) as a model organism to 
study the effects of GH-family peptides, nutritional state, and serum on insulin-like growth factor 
(IGF) and growth hormone receptor (GHR) expression. Gene sequencing and phylogenic 
analysis was applied to characterize a novel GHR.  Real-time quantitative-PCR was used to 
determine IGF and GHR expression levels in liver, muscle, and adipose tissue. Western blotting 
and pharmacological inhibitors were used to determine signaling pathways. 
A novel GHR was characterized and determined to be a type 1 GHR with a diverse 
distribution. It was found to have many features conserved in other GHRs including binding 
regions, a Y/FGEFS motif, cysteine residues, and N-glycosylation sites. Fasting was shown to 
decrease GHR1 expression in the liver, adipose tissue and red muscle. GH and PRL were shown 
to stimulate IGF expression through the ERK, PI3K/Akt, and JAK-STAT signaling pathways. 
GH-stimulated IGF expression was dependent on nutritional state, as GH was only able to 
stimulate IGF expression in fed fish. Nutritional state has no direct effect on GH-stimulated 
GHR expression. Serum was determined to be the mediator of the change in GH sensitivity as 
pre-treatment with serum from cells of an opposite nutritional state caused cells to react like the 
opposite nutritional state in GH-stimulated IGF expression. These findings contribute to the 
understanding of the actions of GH-family peptides and the mechanisms through which GH 
conducts its diverse actions in times of differing nutritional availability. 
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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
The regulation of growth is a highly studied field. Since its first isolation (Li and Evans 
1944), growth hormone (GH) has been studied extensively and reviewed thoroughly over the 
years. GH has been shown to have many different actions across many different organisms, not 
just the most commonly studied area of growth regulation. These other actions include feeding, 
metabolism, reproduction, osmoregulation, immune function, behavior, and lipolysis (Bjornsson 
et al., 2004; Forsyth and Wallis 2002; Moller and Jorgensen 2009; Norbeck et al., 2007; 
Norrelund 2005; Bergan et al., 2015). GH conducts these actions by binding through a growth 
hormone receptor (GHR) and causing a signaling cascade. The mechanisms that GH uses to 
perform this diverse array of actions are not fully understood. In this review, I will discuss GH 
and its regulation, as well as its primary actions of growth promotion. 
Growth hormone 
Growth hormone (GH) is a member of a greater family of somatotropin hormones 
including prolactin (PRL), and somatolactin (SL) (Forsyth and Wallis 2002). PRL has been 
found in most gnathostomes while SL has only been found in bony fishes (Kawauchi and Sower, 
2006). PRL shares growth promoting actions with GH (Rynikova et al., 1988) but also has many 
other actions including osmoregulation (Maetz 1970), metabolism (Vilalba et al., 1991), 
behavior (Blum and Fiedler 1965), reproduction (Dunaif et al., 1982), and immunity (Nagy et al., 
1983). SL is the newest and least studied of these hormones has actions including reproductive 
maturation (Johnson et al., 1997), acid–base balance (Kakizawa et al., 1996), background 
adaptation (Kakizawa et al., 1995), immune function (Calduch-Giner et al., 1998), energy 
mobilization and stress (Rand-Weaver et al., 1993), lipid metabolism and pigmentation (Zhu and 
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Thomas 1997; Fukamachi et al., 2009), and the regulation of chromatophores (Zhu and Thomas 
1997). These hormones are all similar from an evolutionary standpoint and all also have similar 
type I cytokine receptors (Kossiakoff and Vos 1999; Wallis 1992). These hormones, while 
sharing many overlapping functions and evolutionary similarity, also have many differences to 
be studied including their role in growth promoting actions.   
The genetic structure of GH has been conserved through vertebrate evolution. GH is a 
very well-studied hormone, as GH or a GH-encoding cDNA have been discovered in over 100 
different species across all groups of vertebrates (Moriyama et al., 2006). Most vertebrates have 
a single copy of the GH-encoding genes with the exceptions of carpine ruminants (Wallis et al., 
1998) and isospondylid teleosts (Yang et al., 1997) which each have two copies, and higher 
primates which have four copies (Chen et al., 1989). Salmonids, including our research organism 
rainbow trout, contain multiple copies of GH due to recent tetraploidization events (Volff, 2005). 
The gene that encodes GH includes five exons and four introns (Rajesh and Majumdar, 2007) for 
the majority of species while several groups of fish including salmoniforms, perciforms, and 
tetradontiforms have six exons and five introns (Moriyama et al., 2008). 
Growth hormone receptor 
The actions of GH are conducted through a growth hormone receptor (GHR). As 
mentioned earlier, GHRs belong to a class of type 1 cytokine receptor along with many other 
receptors including a PRL receptor, interleukin receptors, and colony-stimulating factor receptors 
(Cosman et al., 1990).  All of these cytokines share a single transmembrane domain (Postel-
Vinay and Finidori, 1995). GHRs are well studied in over 100 different species including over 25 
species of fish with their GHRs identified and sequenced (Reindl et al., 2009; Ellens et al., 
2013). GHR expression is the highest in liver, but GHRs are expressed in many tissues including 
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muscle, adipose, gill, brain, and intestines mirroring the many diverse actions of GH (Kopchick 
and Andry 2000; Very et al., 2005; Walock et al., 2014). Two GHRs are present in mammals due 
to alternative splicing of GHR mRNA (Talamantes and Ortiz, 2002). Similar findings are also 
present in fish with multiple GHRs being present, each encoded from its own mRNA (Perez-
Sanchez et al., 2002). In rainbow trout which possess multiple GHRs, the GHRs are 
differentially expressed (Reindl and Sheridan, 2012). This differential expression is one possible 
cause of the multiple actions of GH.  
GHRs from across multiple species share some general structural traits and have 
conserved features. In the extracellular domain GHRs contain multiple cysteine residues used in 
disulfide bonds that are needed for ligand binding (Fuh et al., 1990). GHRs also share another 
feature called the WXSWX motif in the extracellular membrane (Goffin and Kelly 1997). This 
WXSWX motif is believed to be very important in ligand binding (deVos et al., 1992).  Across 
the intercellular domain GHRs also share similar features called box 1 and box 2 with the other 
members of the cytokine receptor family (Carter-Su et al., 1996).  These areas are highly 
conserved and important in signal transduction as a mutation in either region leads to interruption 
in GHR signal transduction (Baumann et al., 1994). 
GHR signaling 
When GH binds to GHR, the action of GH is mediated through a number of signaling 
pathways. In this review, I will briefly go over some classical signaling pathways used by GHRs. 
When bound by GH a pair of GHR dimers undergoes a conformational change during activation 
(Brown et al., 2005). The most common signaling pathway of cytokine receptors is janus kinase 
(JAK) (Ihle et al., 1995) and specifically for GHR, JAK2. After GH binding JAK2 
phosphorylates the GHR to open binding sites for other signaling elements (Kiu and Nicholson, 
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2012). Traditionally the next signaling elements activated after JAK2 are Signal Transducers and 
Activators of Transcription (STATs) specifically STAT5a and b and to a lesser extent STAT1 
and STAT3 (Herrington et al., 2000).  These activated STATs then dimerize with each other and 
move to the nucleus of the cell where they can bind to DNA to regulate gene transcription (Mohr 
et al., 2012).  The action of STAT5 is crucial to the growth promoting action of GH such as 
insulin-like growth factor (IGF) 1 gene expression (Chia et al., 2006). 
JAK2 can also activate other signaling elements other than STATs. JAK2 has been 
shown to activate the mitogen-activated protein kinase (MAPK) pathway then finally to 
extracellular signal-regulated kinases (ERK1/2) which can then affect gene transcription either 
directly or through transcription factors such as c-AMP responsive element-binding protein (Zhu 
et al., 2001). Additionally JAK2 also activates phosphoinositide 3-kinase (PI3K) (Moutoussamy 
et al., 1998). These are just a few of the signaling elements GH can activate through JAK2 (Zhu 
et al., 2001).  In addition to the many signaling elements GH activates through JAK2 
phosphorylation, GHR activation can cause the phosphorylation of proto-oncogene tyrosine-
protein kinase (c-Src) which is a component of its own signaling pathways independent of JAK2 
(Zhu et al., 1998).  c-Src activation leads to many different growth promoting actions including 
cell cycle control, proliferation, and differentiation (Schlessinger, 2000).  
GH signaling is also controlled by both negative regulators and cross-talk between cell 
signaling pathways. One group of negative GHR regulators is Suppressors of Cytokine Signaling 
(SOCS). SOCS is a group of negative regulators of all cytokine receptor signaling in which the 
action was thoroughly reviewed by Flores-Morales ,(2006). The three major ways through which 
SOCS work are directly blocking JAK2 activation (Yasukawa et al., 1999), binding to tyrosines 
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in the GHR and blocking STAT5b activation (Hansen et al., 1999), and finally degrading GHRs 
through increased ubiquitination (Kamura et al., 2004).  
Protein tyrosine phosphatases (PTPs) are another group of negative regulators of GHR 
signaling. PTPs also block GHR signaling utilizing different mechanisms including PTP-1 
inhibiting STAT5b (Ram and Waxman 1997) and dephosphorylating activated GHR (Gu et al., 
2003). 
GHR signaling cross-talks with multiple other receptor signaling systems and other 
related signaling pathways. Both GH and insulin regulate both growth and metabolism and share 
many similar signaling elements, as thoroughly reviewed by Xu and Messian (2009). Briefly, 
insulin binding to its receptor for a short time is also shown to activate the MAPK pathways 
downstream of GHR but a longer time binding has negative effects through the same pathways. 
Additionally, long term high dose GH treatment has inhibitory effects on insulin signaling 
pathways (IRS1, 2, 3) actions through PI3K. This cross talk and regulatory elements provide 
another possible mechanism though which GH exerts its diverse actions, especially in times of 
fasting as both GH and insulin are involved. 
GH actions 
The primary action of GH is its ability to promote growth. The understanding of how GH 
promotes growth has evolved from the initial discovery of a sulfation factor intermediate in the 
actions of GH in gill sulfur uptake 70 years ago (Salmon and Daughaday, 1957). This discovery 
lead to the naming of the factor as a somatomedin to better describe its actions in mediating the 
growth (Salmon and Daughaday, 1957). This understanding was further expanded with the 
isolation and characterization of IGF 1 and 2 (Rinderknecht and Humbel 1978; Klapper et al., 
1983). These somatomedins were first called insulin-like since they share a similar ability to 
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induce glucose uptake in fat and muscle cells with insulin (Randle 1954). When IGF-1 and IGF-
2 were fully characterized they were found to share approximately 50% amino acid identities 
with insulin (Rinderknecht and Humbel 1978).  
These early discoveries started the original somatomedin hypothesis of growth promotion 
by GH.  This has evolved even further over time to include more diverse actions of GH. The full 
evolution of the somatomedin hypothesis has been thoroughly reviewed (Le Roith et al., 2001). 
GH has been shown to have different growth promoting actions across many different levels. 
Early GH research showed GH to increase protein synthesis in muscle (Kostyo, 1968). In 
addition to the cellular level, GH treatment was shown to increase protein in the whole body 
(Wolf et al., 1992).  
IGF 
Many of the actions of GH are mediated through IGFs. These are many of the most 
studied aspects of GH actions, including in fish, as reviewed by Wood et al., (2005). IGFs have 
many actions, with the primary actions relating to growth including sulfur incorporation (Salmon 
and Daughaday, 1957), cell proliferation (Hu et al., 2004), protein synthesis (Upton et al., 1997), 
smoltification (Madsen and Burns, 2003), and reproduction (Adashi, 1998). The primary location 
of IGF production is the liver but IGFs have been found in almost every tissue (Jones and 
Clemmons, 1995). These sources of IGF outside the liver are very important as they have shown 
the ability to compensate for liver IGF-1 production (Yakar et al., 1999). 
IGF receptors 
IGF receptors (IGFRs) belong to a large family of receptors that include IGFR1, insulin 
receptor, and the IGF-2 mannose-6-phosphate (M-6-P) receptor (Nissley and Lopaczynski, 
1991). IGFRs are expressed in a large number of organs and tissues including brain, muscle, 
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liver, ovary, testis, intestine, and gill (Maures et al., 2002). IGFR1 has been shown to conduct the 
actions of both IGF-1 and IGF-2 (Le Roith et al., 2001). The insulin receptor is primarily 
responsible for the actions of insulin and has also been shown be responsive to IGF-2 in utero 
(Louvi et al., 1997). While the IGFR2 receptor has no effect on IGF signaling it has been shown 
to lower levels of IGF-2 in fetal development (Baker et al., 1993). In salmonids including our 
model organism rainbow trout, multiple IGFR1s (IGFR1A and IGFR1B) have been found (Chan 
et al., 1997). These receptors share similar structures with IGFR1 and the insulin receptors, 
sharing a 60% amino acid identity (Ullrich et al., 1986). 
As mentioned earlier, IGF1R elicits its response through insulin receptor substrates (IRS) 
proteins which interact with the IGFR1 (Butler et al., 1998). These IRS proteins can then utilize 
other signaling elements such as PI3-K (Backer et al., 1993), which is also utilized in GHR 
signal transduction. Through other downstream signaling elements, IRS proteins are also able to 
stimulate the MAPK signaling pathway (Ricketts et al., 1996), which is also utilized by GHR. 
These connections between GH, IGF-1, and insulin greatly connect the shared actions of these 
hormones. 
IGF binding proteins 
Insulin-like growth factor binding proteins (IGFBPs) are proteins that share a very high 
affinity for IGFs. IGFBPs also have been very well studied and reviewed (Jones and Clemmons, 
1995; Wood et al., 2005). Six different IGFBPs have been identified across vertebrates (Daza et 
al., 2011). IGFBPs have been found in many different tissues including brain, liver, muscle, 
intestine, and ovary (Ferry et al., 1999) similar to IGFRs. One of the primary actions is to bind 
free IGFs and protect them from degradation (Le Roith et al., 2001). In mammals 75% of all free 
IGF-1 and IGF-2 are bound by IGFBP-3 (Baxter et al., 1989).  Another action of IGFBPs is to 
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increase the availability of IGF to its receptors (Miyakoshi et al., 2001). IGFBPs can also inhibit 
the actions of IGF, such as IGFBP-4 inhibiting IGF-1-induced myogenesis (Silverman et al., 
1994). In addition to actions utilizing IGFs, IGFBPs have been found to have actions outside of 
IGFs including cell motility and adhesion (Jones et al., 1993). 
IGF regulation 
There are many different regulators of all the components of IGF actions. These have 
been previously reviewed thoroughly (Reindl and Sheridan, 2012). I will briefly share some of 
the related regulators of IGF. The main regulator of IGF expression across all vertebrates is GH 
(Piwien-Pilipuk et al., 2002) with GH stimulating IGF expression. Other hormones have also 
been shown to regulate IGF expression. Somatostatin (SS) has been shown to decrease IGF 
expression in liver (Sheridan and Hagemeister, 2010). Insulin has been shown to decrease IGF-1 
expression (Pierce et al., 2005). Interestingly, insulin was also shown to increase IGF-2 
expression (Pierce et al., 2010). This suggests a possible difference in the actions of IGFs in 
regards to inulin. Similar hormones also have actions on IGFR expression. SS decreases IGFR 
expression in rainbow trout hepatocytes (Very and Sheridan, 2007; Hanson et al., 2009). Insulin 
treatment produced contradictory results causing decreased IGFR expression in trout 
cardiomyocytes (Moon et al., 1996) and increased IGFR expression in the gills (Very et al., 
2008) suggesting differing actions of IGFRs in different tissues. These regulators have a large 
amount of overlap with regards to IGF actions and, taken with IGFBPs, suggest a multilevel 
system of regulation. 
GH regulation 
Circulating levels of GH are kept in balance by both the actions of secretion and 
clearance. GH is created and secreted from somatotroph cells located in the anterior pituitary. 
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GH is also produced in the placenta by mammals. The secretion of GH from the pituitary is 
pulsatile in both birds and mammals (Anthony et al., 1990; Hall et al., 1986). In both rats (Eden, 
1979) and humans (Pincus et al., 1996) sexual differences are noted in this pulsatile pattern with 
males having higher peaks and lower interpeak levels and females have a less pulsatile pattern 
with higher interpeak levels. In rainbow trout the pulsatile pattern is seen but is also highly 
variable and much more complicated (Bjornsson et al., 2002). GH levels in circulation are 
measured in the range of 1-10 ng/ml across most species (Anthony et al., 1990; Einarsdottir et 
al., 2002;  Norbeck et al., 2007; Fox et al., 2010; Salgin et al., 2012). While GH can be observed 
freely in circulation, a large amount 40-50%, is bound by growth hormone binding protein 
(GHBP) (Bauman et al., 1988).  
GH binding proteins 
GHBP is an alternate truncated form of GHR that is formed by the proteolytic cleavage 
of GHR in humans or by the alternative splicing of the GHR mRNA in mice (Leung et al., 2004). 
GHBP is found to be produced primarily in the liver (Amit et al., 2000), but is also expressed in 
multiple tissues outside of the liver (Barnard et al., 1994). GHBP is known to exist in three 
different forms: freely circulating, membrane bound, and intracellular.  
GHBP plays a major role in regulating the actions of GH. Contradictory actions both 
promote and inhibit the activity of circulating GH. GHBP is shown to bind to circulating GH and 
protect it from degradation, thus, increasing its half-life (Turyn et al., 1997) and increasing the 
chance of GH actions due to its prolonged availability. GHBPs have also been shown to bind 
competitively with GHR for the binding of GH, thus, limiting GH action (Mannor et al., 1991). 
GHBP delivers GH to GHR to help facilitate binding (Fisker 2006). While much more is known 
about GHBPs in mammals where the majority of the research has been done, little is known 
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about GHBPs in fish. In rainbow trout GHBP has been discovered (Sohm et al., 1998) but little is 
known about its actions. 
Hormonal GH regulation 
The regulation of GH is complicated. Many different factors including hormones, 
environmental state, and nutritional state all regulate GH. The regulation of GH starts directly 
with the regulation of GH by the hypothalamus. The hypothalamic control of GH is both 
stimulatory and inhibitory. GH releasing factors (GRFs) have been shown to stimulate the 
secretion of GH and have been found in all vertebrate groups (Hall et al., 1986). While GRFs 
have been found in every vertebrate group, they are not the same across all species (Harvey, 
1993). GH-releasing hormone (GHRH) is considered to be the major GRF in mammals and 
higher vertebrates (Spiess et al., 1983). GHRH does stimulate GH release in fish (Peng and 
Peter, 1997) but with a much lower efficacy. This suggests that GHRH is not the major GRF in 
fish (Montero et al., 2000). The opposite holds true for major GRFs in fish, amphibians, and 
reptiles, such as pituitary adenylate cyclase activating polypeptide (PACAP) and corticotropin-
releasing hormone (CRH),  which are not active in mammals (Rousseau and Dufour, 2007). In 
fact, research on PACAP on the stimulation of GH release in mammals is contradictory; some 
research has shown PACAP to stimulate GH release (Nagy et al., 1993) whereas others have 
shown it to have no effect at all (Miyata et al., 1989). While GHRH and PACAP are both 
members of the same family (Vaudry et al., 2000), it is believed that GHRH did not become the 
major GRF until subsequent vertebrate evolution (Montero et al., 2000). 
The major inhibitor of GH stimulation at the hypothalamic level is a family of hormones 
called somatostatins (Rousseau and Dufour, 2007). Somatostatins are a group of hormones with 
sizes ranging from 14-17 amino acids and have been found in every major group of vertebrates 
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(Sheridan et al., 2000). SS was first found as a 14 amino acid peptide in sheep (Brazeau et al., 
1973), and this form has been found in every vertebrate group (Nelson and Sheridan, 2005). The 
main action of SS for which it was named is the direct inhibition of GH secretion (Brazeau et al., 
1973). SS has also been shown to decrease the stimulation of GH secretion caused by other 
GRFs including PACAP and CRH (Lin and Peter 2001). SS has also been shown to inhibit 
GHRH release (West et al., 1997), itself being another major GRF. Additionally, while SS is 
shown to decrease GH stimulation, it does not affect GH expression (Fukata et al., 1985).  
A number of other hormones also act to regulate GH expression. One such group of 
hormones are thyroid hormones. Thyrotropin-releasing hormone (TRH) has been shown to 
increase GH secretion in goldfish (Trudeau et al., 1992) as well as increasing GH protein 
production in goldfish pituitaries (Kagabu et al., 1998). TRH then stimulates the release of 
thyroid-stimulating hormone (TSH) which itself has also been shown to directly stimulate GH 
release (Melamed et al., 1998).  An additional level of GH regulation is also found when 
Triiodothyronine (T3),   a thyroid hormone whose release is stimulated by TSH, has also been 
shown to stimulate GH synthesis (Melamed et al., 1995). This information all taken together 
illustrates a multi-level system of GH regulation by thyroid hormones. 
GH feedback inhibition 
The regulation of GH also occurs at levels beyond hypothalamic control. GH is known to 
be regulated by long-loop negative feedback inhibition though IGFs (Wong et al., 2006). 
Wherein GH stimulates IGF expression in the liver which itself later acts to decrease both GH 
release and GH mRNA levels (Weil et al., 1999). The inhibition of GH by IGF works through 
different signaling pathways. The inhibition of GH secretion is through PI3K and MAPK 
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signaling pathways (Fruchtman et al., 2001), while the inhibition of GH expression is though 
calcineurin (Huo et al., 2006). 
Environmental GH regulation 
Many different environmental effects also control the regulation of GH. These effects are 
well studied in salmonids. Photoperiod is a one well studied effector of GH expression. 
Perceived photoperiod in salmon regulated endocrine cells including the somatroph cells in the 
pituitary that produce GH (Komourdjian et al., 1976). This was later confirmed by experiments 
that showed that increased day lengths lead to an increase in circulating GH levels in salmon 
undergoing smoltification (Björnsson et al., 1995; McCormick et al., 1995). Smoltification is a 
common stage to study the effects of photoperiod in light because of the natural exposure of the 
salmon to longer days as early in the process of adapting to saltwater. This increase in GH is also 
important because GH helps shift the metabolic demands of fish towards smoltification (Winans 
and Nishioka 1987). Additionally, GH helps fish in early smoltification through a large number 
of osmoregulatory changes (Sakamoto et al., 1993). GH has also been shown to be regulated by 
temperature as fish raised in warmer water were shown to have higher levels of GH (Björnsson 
et al., 1989). 
Fasting 
Fasting has been well established to have a role on the regulation of GH. Fasting has 
actions on GH, GHRs IGFs, IGFBPs and other related hormones. I will combine the effects of 
nutrition together into a brief summary as this is important to my research. First fasting has been 
shown to increase circulating GH levels in many species (Gomez-Requeni et al., 2005; Norbeck 
et al., 2007; Picha et al., 2008; Reinecke, 2010). This is the first conflict because GH is most 
often associated with growth promoting actions, which do not occur during fasting. Fasting has 
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also been shown to decrease other related elements including insulin and IGF-1 (Gomez-Requeni 
et al., 2005; Norbeck et al., 2007) maintaining the trend of GH not promoting growth in times of 
fasting. Fasting has also shown to decrease GHR levels in liver (Small et al., 2006; Norbeck et 
al., 2007) while causing increased GHR levels in muscle (Pierce et al., 2007) and in adipose 
tissue (Norbeck et al., 2007), suggesting a difference in GH actions in different tissues during 
fasting. 
Similar tissue specific and receptor differences were also observed IGFRs in regards to 
fasting. In cardiac muscle, fasting resulted in increased IGFR1A and IGFR1B expression and 
improved IGF binding (Norbeck et al., 2007), additionally, fasting had no effect on IGFR1 
expression in skeletal muscle but IGFR1 expression was decreased in the gill during fasting. The 
effects of fasting on IGFBPs have also been studied, with fasting having different effects on 
different IGFBPs. IGFBP-1 has been shown to increase during fasting (Lee et al., 1997), whereas 
in mammals IGFBP-3 levels decrease in fasting (Clemmons and Underwood, 1991). The 
decrease in smaller IGFBPs, such as IGFBP-1, associated with fasting has been hypothesized as 
a mechanism to stop anabolic processes in times of fasting (Lee et al., 1997). 
Conclusion 
The GH family of hormones, GH, PRL, and SL, have been very well studied and have 
diverse actions in areas including growth, feeding, metabolism, reproduction, osmoregulation, 
immune function, behavior, stress, chromatophore regulation, pigmentation, and lipolysis. While 
the most studied actions of these hormones are growth related, many of them are not and only 
occur during times of catabolism. While well studied, all aspects of GH family hormones actions 
on growth are not known, additionally the full extent of how GH regulates these very different 
actions is not understood. Some of the opposite GH actions occur in the same tissues and it is 
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unknown what factors change these cells responsiveness to GH including the underlying 
signaling mechanisms that change to enable this switch. Many regulatory elements of the GH 
pathway are well studied individually but their interactions together, and upon each other, are not 
fully understood.  
While GHRs are very well studied, the roles of individual GHR subtypes are not fully 
known, especially in animals that possess high numbers of GHRs. For example, a newly 
discovered GHR in rainbow trout has not been thoroughly examined. Many different elements of 
this new GHR are unknown including its characterization, function, and distribution. This new 
GHR will also need to be studied in the evolutionary relationship with other GHRs.  The many 
actions on GH by fasting has been studied at multiple levels, but a fuller understanding of how 
nutrition can change organisms via GH is not known. Specifically, it’s not fully known how cells 
responsiveness to GH changes under different nutritional states. Overall a better understanding 
of the growth-promoting actions of GH, specifically in regards to fasting is important to fully 
understand the diverse actions of GH. 
Objectives 
My aim in this dissertation work was to add to the overall understating of the growth 
promoting actions of GH especially as related to fasting. This primary goal will be achieved 
through 3 goals: (1) characterize a newly discovered GHR and test the effects of fasting on its 
expression, (2) study the differing effects of the growth hormone family peptides on the growth-
promoting actions of IGF and GHR expression, and, (3) test the effect of fasting on the growth-
promoting actions of GHIGF and GHR expression. Additionally, I investigated the effects of 
serum on fasting induced changes in GH sensitivity. In both the second and third goals, 
pharmacological inhibitors were also used to assess which signaling pathways are being utilized. 
 15 
The intent of these studies is to help in understanding how GH conducts such an array of diverse 
actions. 
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CHAPTER 2: CHARACTERIZATION OF A NOVEL GROWTH HORMONE 
RECEPTOR-ENCODING CDNA IN RAINBOW TROUT AND REGULATION OF ITS 
EXPRESSION BY NUTRITIONAL STATE
1
. 
Abstract 
To clarify the divergence of the growth hormone receptor (GHR) family, we 
characterized a novel GHR from a teleost fish (rainbow trout).  A 2357-nt cDNA was isolated 
and found to contain a single initiation site 71 nt from the most 5’ end, and open reading frame 
of 1971 nt encoding a 657-amino acid protein, and a single polyadenylation site 229 nt from the 
poly-A tail.  Based on structural analysis, the protein was identified as type 1 GHR (GHR1).  The 
new GHR1 shares 42% and 43% amino acid identity, respectively, with GHR2a and GHR2b, the 
two type 2 GHRs isolated from trout previously. GHR1 mRNA was found in a wide array of 
tissues with the highest expression in liver and white muscle. Fasting animals for 4 weeks 
reduced steady state levels of GHR1 in liver, adipose, and red muscle. These findings help 
clarify the divergence and nomenclature of GHRs and provide insight in function of duplicated 
GHR types.  
Introduction 
Growth hormone (GH) plays important roles in the growth, metabolism, reproduction, 
immune function, osmoregulation, and other physiological functions of vertebrate animals 
(Bjornsson, 1997; Bjornsson et al., 2002; Norrelund, 2005; Moller and Jorgensen, 2009).  The 
actions of GH are transduced through the GH receptor (GH), a member of the class-I cytokine 
receptor superfamily that consist of an extracellular binding domain containing a conserved  
1
 This chapter has been published as follows: Walock, C.N., Kittilson, J.D., Sheridan, M.A.  2014. Characterization 
of a novel growth hormone receptor-encoding cDNA in rainbow trout and regulation of its expression by nutritional 
state. Gene 533:286–294 As lead author, I wrote the manuscript, conducted all the experiments, analyzed all data, 
and made all figures for this chapter. 
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Y/FGEFS motif, a single transmembrane domain, and an intracellular domain that links to 
several cellular effector pathways, including JAK-STAT, ERK, and PI3K-Akt (Kopchick and 
Andry, 2000; Forsyth and Wallis, 2002; Waters et al., 2006). 
The GHR family arose through a series of genome duplication events (1R-3R) during the 
course of vertebrate evolution (Liongue and Ward, 2007; Ellens and Sheridan, 2013; Ellens et 
al., 2013).  The first two events are believed to have occurred early in chordate evolution, with 
the 2R event perhaps taking place before the cyclostome-gnathostome split (Van de Peer et al., 
2009).  The 3R event, also known as the fish-specific genome duplication (FSGD) event 
occurred in the actinopterygian lineage (ray-finned fishes) after divergence from the 
sarcopterygian lineage (lobe-finned fishes; includes the common ancestor of the tetrapods) 
(Meyer and Van de Peer, 2005).  The FSGD likely explains the existence of multiple GHRs that 
derive from distinct mRNAs in boney fish (teleosts), whereas tetrapods possess a single GHR 
gene (Ellens and Sheridan, 2013).  Several groups of teleosts, including the salmonids underwent 
a subsequent independent duplication event (4R) (Meyer and Van de Peer, 2005).  It is not 
surprising, then, that the divergence of GHRs and their nomenclature are somewhat confused 
(Fukamachi and Meyer, 2007; Ellens and Sheridan, 2013; Ellens et al., 2013).  For example, the 
terms “GHR1” and “GHR2” were first used for naming GHR subtypes in tetraploid salmonids 
(cf. Very et al., 2005); this scheme continued for other groups of teleosts (cf. Ellens and 
Sheridan, 2013).   
The aim of this study was to clarify the divergence and nomenclature of GHRs. We used 
rainbow trout to further study the polygenic origins of GHRs and to provide insight into the 
functional significance of duplicated GHR subtypes.  
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Materials and methods 
Experimental animals 
Rainbow trout (Oncorhynchus mykiss) were selected because 1) as teleosts they occupy a 
pivotal point in vertebrate evolution (Van de Peer et al., 2009; Ellens and Sheridan, 2013b), they 
underwent a tetraploidization event subsequent to the FSGD (Meyer and Van de Peer, 2005), we 
previously isolated two GHR paralogs from them (Very et al., 2005).  Juvenile fish of both sexes 
were obtained from Dakota Trout Ranch near Carrington, ND and transported to North Dakota 
State University where they were maintained in 800 L circular tanks supplied with recirculated 
(10% replacement volume per day) dechlorinated municipal water at 14 °C under a 12L:12D 
photoperiod. Fish were fed to satiety twice daily with AquaMax™ Grower (PMI Nutrition 
International, Brentwood, MO, USA), except 36–48 h before experimental manipulations. 
Animals were acclimated to laboratory conditions for at least 4 weeks prior to experiments. All 
procedures performed were in accordance with the Guide for Care and Use of Laboratory 
Animals (National Research Council, Washington, DC) and approved by the North Dakota State 
University Institutional Animal Care and Use Committee. 
For the nutritional state experiments, fish were assigned randomly to one of six treatment 
groups (initial, fed continuously for 2 weeks, fasted for 2 weeks, fed continuously for 4 weeks, 
fasted for 4 weeks, and fasted for 2 weeks then refed for 2 weeks) in 100-L circular tanks 
(approximately 18–24 fish per tank) with a flow-through water supply at 14 °C under a 12:12 
L:D photoperiod. Fish were allowed to acclimate for 2 days in their experimental tank prior to 
beginning their respective nutritional regime. For those animals receiving food, feeding was 
suspended 24–36 h before sampling. At the time of sampling, fish were anaesthetized in 0.05% 
(v/v) 2-phenoxyethanol, measured (body weight, length, and liver weight), bled via the severed 
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caudal vessels, and euthanized by transection of the spinal cord. Samples of liver, mesenteric 
adipose tissue, white skeletal muscle, and red skeletal muscle were removed, frozen on dry ice, 
and stored at −80 °C for later analyses. 
RNA extraction 
Total RNA was extracted using TRI-Reagent® as specified by the manufacturer 
(Molecular Research Center, Cincinnati, OH, USA). Isolated RNA was dissolved in 
approximately 100 μL RNase-free deionized water. Total RNA was quantified by ultraviolet 
(A260) spectrophotometry and diluted to 100 ng/μL in RNase-free deionized water. RNA 
samples were then stored at −90 °C until further analysis. 
Oligonucleotide primers and probes 
Gene-specific primers used for isolation of cDNAs were custom synthesized by Sigma-
Genosys (The Woodlands, TX, USA, USA). Additional primers for reverse transcription were 
provided in SMART™ RACE cDNA Amplification Kit (Clontech, Mountain View, CA, USA) 
and AffinityScript™ QPCR cDNA Synthesis Kit (Agilent Technologies Santa Clara, CA, USA). 
Gene-specific oligonucleotide primers and probes used for real-time PCR of GHR and β-actin 
were designed based upon our determined and known sequences (GenBank accession no. 
AF157514), respectively, using ABI Primer Express® Version 2 software and custom 
synthesized by Applied Biosystems (Life Technologies Applied Biosystems Carlsbad, CA, 
USA). The probes were minor-groove binding probes labeled with either FAM (GHR1) or VIC 
(β-actin probe). Primers and probes were used for reverse transcription and PCR without further 
purification. 
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 Isolation and sequence analysis of growth hormone receptor cDNA 
A two-phase approach was adopted for the isolation of selected cDNAs using and 3’-
rapid amplification of cDNA ends (3’-RACE)-PCR (Phase 1) and RT-PCR (Phase 2). 3′-RACE 
PCR was performed using a SMART™ RACE cDNA Amplification Kit (BD Biosciences 
Clontech, Palo Alto, CA, USA) following the manufacturer's protocol. RNA from rainbow trout 
liver was reverse transcribed into cDNA containing the sequence tags necessary for SMART™ 
chemistry. The PCR was carried out using a 3’RACE gene-specific primer (Table 1) designed 
from partial GHR sequences in GenBank (accession nos. AF438178 and DQ452378). After an 
initial denaturation at 94 °C for 5 min, a 35-cycle PCR was performed with each cycle consisting 
of denaturation (94 °C for 30 sec), annealing (65 °C for 30 sec), and extension (72 °C for 1 min) 
phases. In the last cycle, the extension time was increased to 10 min. The PCR product was 
identified by electrophoresis on an agarose gel containing 1% of each OmniPur (EMD 
chemicals, Gibbstown, NJ, USA) and NuSieve GTG agarose (BioWhittaker Molecular 
Applications, Rockland, ME, USA) in 1× Tris–borate–EDTA (TBE) buffer followed by 
ethidium bromide staining. The resulting PCR product was cloned into the pGEM-T Easy Vector 
(Promega, Madison, WI, USA). Purified plasmids (75 fmol) were sequenced using the CEQ 
2000 Dye Terminator Cycle Sequencing with Quick Start Kit (Beckman Coulter, Fullerton, CA, 
USA) according to the manufacturer's protocol. 
Phase 2, RNA was reverse transcribed as described earlier and PCR was carried out using 
primers designed from our 3’RACE product and partial GHR sequences in GenBank (accession 
nos. AF438178 and DQ452378)(Table 1). After an initial denaturation at 94 °C for 5 min, a 35-
cycle PCR was performed with each cycle consisting of denaturation (94 °C for 1 min), 
annealing (65 °C for 30 sec), and extension (72 °C for 2 min) phases. In the last cycle, the 
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extension time was increased to 10 min. The resulting PCR product was visualized, cloned into 
the pGEM-T Easy Vector, and sequenced as described previously.  
Table 1   
Primers and probes used for sequence analysis and for real-time quantitative PCR. 
Target Description Sequence 
GHR1 
 
Phase I sequence analysis 
3’RACE gene-specific primer 
 
5’-TCCTGCCAACCCAACAAAGT-3’ 
   
GHR1 
 
 
Phase II sequence analysis 
Forward primer 
Reverse primer 
 
5’-GAAGTCGATACCCCTCGCGCAT-3’ 
5’-TGGGCAGTGTAGTTTTTCTTAAGG-3’ 
   
GHR1 
 
 
 
QPCR analysis 
Probe 
Forward primer 
Reverse primer 
 
5’FAM-TGCGTGTGCACTGTG-MGBNFQ3’   
5’-TCAGACAGGAGAGGCGTACGA-3’ 
5’-CCAAAGTTATTGAAGGCCCTCAT-3’ 
   
β-actin 
 
 
 
QPCR analysis 
Probe 
Forward primer 
Reverse primer 
 
5’VIC-TGCTTGCTGATCCACAT-MGBNFQ3’ 
5’-GGCTTCTCTCTCCACCTTCCA-3’ 
5’-AGGGACCAGACTCGTCGTACTC -3’ 
Abbreviations:  GHR, growth hormone receptor; QPCR, Real-time quantitative PCR. 
 
Real-time PCR assay for growth hormone receptor mRNA 
Preparation of cDNA standards 
A cDNA standard for GHR1 was synthesized by PCR.  Approximately 1 μg of the full 
GHR cDNA product was used as template for PCR using forward and reverse gene-specific 
primers (Table 1) under the same conditions as described above. The resulting PCR product was 
visualized, cloned into the pGEM-T Easy Vector, and the sequences verified as described 
previously. 
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Real-time reverse transcription PCR 
From 200 ng total RNA, endogenous poly(A)+ RNA was reverse transcribed in a 5 μL 
reaction using a SMART™ RACE cDNA Amplification Kit containing a RNase H+ reverse 
transcriptase and a blend of oligo(dT) and random hexamer primers according to the 
manufacturer’s instructions. Reactions without reverse transcriptase were included as negative 
controls; no amplification was detected in negative controls. 
mRNA levels of GHR1 were determined by real-time RT-PCR using Stratagene Brilliant 
II QPCR mastermix and a STRATAGENE MX3000P® Detection System (Stratagene, La Jolla, 
CA, USA ). Real-time PCRs were carried out for samples, standards, and no-template controls in 
a 10 μL reaction, containing 2 μL (20 ng) cDNA, 1 μL each forward primer GHR1 (600 nM); β-
actin; (900 nM), reverse primer GHR1 (600 nM);  β-actin (900 nM), and probe GHR1; (150 
nM); β-actin (150 nM) (Table 1) at optimized concentrations for the mRNA species to be 
measured, and 5 μL TaqMan Universal PCR Master Mix. Cycling parameters for real-time PCR 
were as follows: 95 °C for 10 min, and 40 cycles of 95 °C for 30, 62 °C for 15 s, and 72°C for 30 
s. PCR efficiency for GHR1 was 99.8%. To verify the specificity of the assays, cross 
hybridization was assessed by substituting alternate primer/probe sets in TaqMan reactions for 
each standard. No amplification was observed with mismatched primer/probe sets. 
Copy number calculations were based on threshold cycle number (CT). The CT for each 
sample was determined by the MX3000P™ real time analysis detection software after manually 
setting the threshold. Sample copy number was determined by relating CT to a gene-specific 
standard curve, followed by normalization to β-actin. No difference (P > 0.05) was observed in 
β-actin expression among the various treatment groups. No-template control samples reached a 
maximum ΔRn of 0.03 at 40 cycles. Therefore, copy numbers of mRNA were considered non-
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significant if CT exceeded 44 cycles; this value corresponds to a detection limit of less than 100 
mRNA copies.  
Data analysis 
The nucleotide and associated protein sequences were aligned and analyzed with 
GeneTool and PepTool sequence analysis programs, respectively (BioTools Inc., Edmonton, 
Alberta, Canada). Clustal X (default parameters, except corrected for multiple substitutions) was 
used in conjunction with the neighbor-joining method to generate the phylogenetic tree; the tree 
was visualized with TreeView and rooted to the lamprey GHR/PRLR.  Only completely 
overlapping sequences containing 200+ amino acids were used in the analysis. Quantitative data 
are expressed as means ± SEM. Statistical differences were estimated by ANOVA followed by 
Duncan’s multiple range test; a probability level of 0.05 was used to indicate significance. All 
statistics were performed using SigmaStat (SPSS, Chicago, IL, USA). 
Results 
Characterization of a new GHR1 mRNA 
Phase 1 3’-RACE PCR yielded a cDNA fragment approximately 1100 nt in length (Fig. 
1).  Sequence analysis of the fragment indicated the successful isolation of a novel GHR.  Based 
upon the 3’-RACE product, a second set of gene-specific primers was designed.  Phase 2 RT-
PCR yielded a cDNA fragment approximately 2000 nt in length (Fig. 1).  Assembly of the 
fragments revealed a 2357-nt full-length cDNA containing a 70-nt 5’-untranslated region (UTR), 
a 1971-nt coding sequence of 1971bps, and a 316-nt 3’-UTR (Fig. 2).   
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Fig. 1. PCR products resulting from 3’-RACE- (Phase 1) and reverse transcription-PCR (Phase 
2) with growth hormone receptor gene-specific primers. PCR reactions were conducted as 
described in the Materials and Methods section. PCR products were separated by agarose gel 
electrophoresis and visualized by ethidium bromide staining and UV transillumination. M1, 
100bp molecular weight marker; M2 1kb molecular weight marker; lane A, PCR product 
resulting from 3’-RACE PCR; lane B, PCR product resulting from RT-PCR. 
 
Based upon comparison with known GHR sequences (cf. Ellens et al., 2013), we 
identified the novel GHR as a teleost type 1 GHR (GenBank accession no. JQ408978). The 
rainbow trout GHR 1 cDNA encodes a 657-amino acid protein that shares 42% and 43 %, 
respectively, amino acid identity with the two GHRs characterized from rainbow trout previously 
(Very et al., 2005).  As a result, we were able to design real-time PCR primers that were able to 
detect only rainbow trout GHR1 mRNA; the primer set (Table 1) did not amplify either of the 
two other rainbow trout GHRs (Fig. 3). 
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Fig. 2. Nucleotide and deduced amino acid sequences of rainbow trout growth hormone receptor 
1 (GHR1).  Nucleotides are numbered 5’ to 3’ and the amino acid residues (denoted using single-
letter abbreviations) are numbered beginning at the initiation methionine. Selected regions are 
denoted as follows: signal peptide (underlined), conserved cysteine residues in the extracellular 
domain (circled), potential N-glycosylation sites (boxed in squares), site B (underlined with 
dashes), FGEFS motif (bold), transmembrane domain (dashed box), Box 1 and Box 2 (boxed in 
rectangles), tyrosine residues in the intracellular domain (diamonds), and stop codon (*). 
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Fig. 2. Nucleotide and deduced amino acid sequences of rainbow trout growth hormone receptor 
1 (GHR1) (continued). Nucleotides are numbered 5’ to 3’ and the amino acid residues (denoted 
using single-letter abbreviations) are numbered beginning at the initiation methionine. Selected 
regions are denoted as follows: signal peptide (underlined), conserved cysteine residues in the 
extracellular domain (circled), potential N-glycosylation sites (boxed in squares), site B 
(underlined with dashes), FGEFS motif (bold), transmembrane domain (dashed box), Box 1 and 
Box 2 (boxed in rectangles), tyrosine residues in the intracellular domain (diamonds), and stop 
codon (*). 
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Fig. 3. Quantitative real-time PCR of trout growth hormone receptor 1 (GHR1) mRNA. Sample 
copy number was determined by relating CT to a standard curve (A) comprised of serial 
dilutions of known amounts of each GHR1 cDNA, then normalized to β-actin levels. 
Representative amplification plot of GHR1 mRNAs by real-time RT-PCR (B) . Abbreviation: 
NTC, no-template control. 
 
Differential expression of GHR1 mRNA among tissues 
RNA from various tissues was isolated and reverse transcribed and the cDNA encoding 
GHR1 was quantified using real-time PCR.  Although GHR1 mRNA was detected in every 
tissue examined, the abundance of GHR1 mRNA varied among tissues (Fig. 4). The highest 
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levels of GHR1 mRNA were found in liver and white muscle.  Intermediate expression of GHR1 
mRNA was found in brain, endocrine pancreas, gill, and adipose tissue. The lowest levels of 
GHR mRNA were detected in spleen.  
 
Fig. 4. Abundance of growth hormone receptor 1 (GHR1) mRNA in various tissues of rainbow 
trout.  mRNAs were quantified by real-time RT-PCR.  Data are represented by ± SEM (n=8). 
Groups with different letters are significantly (P<0.05) different from each.  Abbreviations: LIV, 
liver; WM, white muscle; BRN, brain; PIT, pituitary; HRT, heart; PAN, pancreas; ESO, 
esophagus; PC, pyloric ceca; STO, stomach; UI, upper intestine; LI, lower intestine; GILL, gill 
filament; KID, kidney; ADP, adipose; and SPN, spleen. 
 
Effects of nutritional state on GHR1 mRNA expression 
The pattern of GHR1 mRNA expression was modulated by nutritional state (Fig. 5).  
Short-term (2 weeks) decreased levels of GHR1 mRNA in adipose tissue and red muscle. Long-
term (4 week) fasting resulted in reduced expression of GHR1 mRNA in liver as well as 
continued fasting-associated diminution of GHR1 mRNA levels in adipose tissue and red 
muscle.  Refeeding restored GHR1 expression in liver and adipose tissue to levels observed in 
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continuously fed animal; refeeding also increased levels of GHR1 mRNA in red muscle above 
those seen in fasted fish, but not significantly. Nutritional state did not have a significant effect 
on GHR1 expression in white muscle (Fig. 5).   
 
Fig. 5. Effects of nutritional state on the expression of growth hormone receptor 1 (GHR1) in (A) 
liver, (B) mesenteric adipose tissue, (C) red muscle, and (D) white muscle of rainbow trout. Data 
presented as % change from fed controls and expressed as means ± SEM (n=8). Groups with 
different letters are significantly (P < 0.05) different from each other. 
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Discussion 
In this study, we characterized a cDNA encoding a novel GHR in rainbow trout. This 
new GHR helps clarify the divergence of GHRs in vertebrates, and based on the pattern of 
divergence, we identified it as a teleost type 1 GHR (GHR1).  The GHR1 mRNA is widely yet 
differentially expressed among tissues in rainbow trout, consistent with the pleiotropic actions of 
GH (Bjornsson, 1997; Bjornsson et al., 2002; Norrelund, 2005; Moller and Jorgensen, 2009).  In 
general, steady state levels of trout GHR1 mRNA were significantly lower than those of trout 
GHR2 mRNAs (Very et al 2005). The predicted rainbow trout GHR1 protein possesses structural 
features conserved in vertebrate GHRs: an extracellular domain containing hormone binding 
regions, a Y/FGEFS motif, and conserved cysteine residues and N-glycosylation sites; a single 
transmembrane domain; and an intracellular domain containing conserved phosphorylation sites 
for linkage to effector pathways.   
Until now, the origins of the multiple GHRs in teleosts and their names were confusing, 
and it was unclear whether a particular GHR form in teleosts was a result of the FSGD event 
(3R) or a more recent tetraploidization (4R).  We conducted a new phylogenetic analysis 
comparing the novel trout GHR with all other known GHRs from teleosts and selected other 
vertebrates (Fig. 6).  The pattern that emerges is consistent with known vertebrate evolution and 
indicates that gnathostome GHRs arose from a common GHR/prolactin (PRL) receptor gene in 
agnathostomes (Ellens et al., 2013).  Subsequently, the sarcopterygian lineage (lobe-finned 
fishes; includes the common ancestor of the tetrapods) diverged from the actinopterygian lineage 
(ray-finned fishes).  Although the precise timing of the FSGD event is not certain, it appears to 
be after the divergence of chondrostei (represented by sturgeon) from the common ancestor of 
teleosts (Fukamachi and Meyer, 2007).  Within the teleosts there are two distinct GHR clades.   
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Fig. 6.  Phylogenetic tree of the known growth hormone receptors (GHR) of fish and selected 
other vertebrates.  The tree was based on the alignment of amino acid sequences using the N–J 
bootstrap method in Clustal X and considered only completely overlapping segments greater 
than 300 nt in length. The tree was rooted using the lamprey GHR/PRLR receptor as an out 
group and was visualized with TreeView. The branch lengths represent amino acid substitutions 
per site from a common ancestor and are proportional to the estimated time since divergence 
occurred. The nomenclature for a particular receptor reflects that given by the authors originally 
or that which appears in databases; if the sequence was not annotated or the receptor 
type/subtype was not specified, the designation on the tree is ours and was chosen for 
consistency with the phylogenetic analysis and our proposed nomenclature. Sequences were 
obtained from either this study, GenBank, (accession numbers in parentheses) or Ensembl 
(protein ID  numbers in parentheses) as follows: Atlantic halibut GHR (DQ062814),  Atlantic 
salmon GHR1 (NM001123576),   Atlantic salmon GHR2  (NM001123594), Atlantic salmon 
SLR (NM001141617), black seabream GHR1 (AF502071), black seabream GHR2 (AY662334), 
Catla GHR (AY691178),  Channel catfish GHR (DQ103502), chicken GHR (NM_001001293), 
Chilean flounder GHR1 (EU004149), Coelacanth GHR (ENSLACG00000005546), coho salmon 
GHR1 (AF403539), coho salmon GHR2  (AF403540), common carp GHR (AY741100), frog 
GHR (AF193799), gilthead seabream GHR1 (AF438176), gilthead seabream GHR2 
(AY573601), goldfish GHR (AF293417), grass carp GHR (AY283778), Japanese crucian carp 
GHR (ADZ13485), Japanese eel GHR1 (AB180476), Japanese eel GHR2 (AB180477), Japanese 
flounder GHR (AB058418), Japanese medaka GHR (NM_001122905),  Japanese medaka SLR 
(NP_001098560), jian carp GHR1a (ADC35573), jian carp GHR1b (ADC35574), jian carp 
GHR2a  (ADC35576),  jian carp GHR2b (ADC35577), lamprey GHR/PRLR (KF034534),  
lungfish GHR (EF158850), masu salmon GHR (AB071216), masu salmon SLR (AB121047), 
Mozambique tilapia GHR1(AB115179), Mozambique tilapia GHR2 (EF452496), Mrigal carp 
GHR (AY691179), Nile tilapia GHR1 (AY973232), Nile tilapia GHR2  (AY973233), opossum 
GHR  (NM001032976), orange spotted grouper GHR1 (EF052273), orange spotted grouper 
GHR2  (EF052274), orangefin labeo GHR (EU147276),  pigeon GHR  (D84308), rainbow trout 
GHR1 (JQ408978), rainbow trout GHR2a (NM001124535), rainbow trout GHR2b 
(NM001124731), rainbow trout PRLR  (AF229197), rat GHR (NM017094), rohu labeo GHR  
(AY691177), South American cichlid SLR (FJ208943), southern catfish GHR1 (AY336104), 
southern catfish GHR2  (AY973231),  stickleback GHR1 (ENSGACT00000009099), stickleback 
GHR2 (ENSGACT00000023732), sturgeon GHR (EF158851), Takifugu GHR1 (BAK86396), 
Takifugu GHR2 (BAK86397), Tetraodon GHR  (ENSTNIP00000004152),  tongue sole GHR1 
(FJ608664), turbot GHR (AF352396),  turtle GHR (AF211173), wami tilapia GHR1 
(EF371466), wami tilapia GHR2 (EF371467), Wuchang bream GHRa (AFC38427), Wuchang 
bream GHRb (AFC38428), yellowfin seabream GHR2 (AEW29012), zebrafish GHRa 
(EU649774), zebrafish GHRb (EU649775).                  
 
GHRs in one of the clades resemble those of sturgeon and the sarcopterygians and appear 
to be their homologs (type 1; Fig 6), whereas the other clade contains GHRs that appear to be 
fish-specific paralogs (type 2; Fig. 6) (Fukamachi and Meyer, 2007; Ellens et al., 2013).  Several 
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groups of teleosts, including the salmonids underwent a subsequent independent duplication 
event (4R) (Meyer and Van de Peer, 2005). 
Unfortunately, the naming of GHRs occurred before this pattern was clear and the terms 
“GHR1” and “GHR2” were applied inconsistently. It is now imperative to revise the 
nomenclature to be consistent with the evolutionary origins of the GHR family.  Accordingly, 
Ellens et al. (2013) proposed a nomenclature system in which different numbers be used to 
designate genes derived from the FSGD event and that different letters be used to designate 
paralogs derived from a subsequent round of duplication. In applying this naming scheme to our 
current analysis the type 1 GHR and type 2 GHRs which emerged during the FSGD event should 
be termed GHR1s and GHR2s, respectively. In some groups, subsequent duplication events gave 
rise to receptor subtypes.  In the salmonids, for example, despite exhaustive screening only a 
single GHR1 could be isolated, suggested that its paralog was lost; however, in most species so 
far examined both type 2 GHR subtypes have been characterized. Applying the nomenclature 
system of Ellens et al. (2013), these subtypes should be designated GHR2a and GHR2b.  This 
will require revision of existing names (as well already have done for rainbow trout; otherwise 
names originally given by authors appear in Fig. 6), to reduce confusion (e.g. salmonid “GHR1” 
and “GHR2’ both being within the type 2 clade).  In order to better represent the evolution of 
GHR family members, Ellens et al. (2013) also urged abandoning the term “somatolactin 
receptor (SLR)” to designate members of the teleost type 1 GHR clade. 
Rainbow trout GHR1 contains several features, including a Y/FGEFS motif, conserved 
cysteines, potential N-linked glycosylate sites, and hormone binding regions, that are conserved 
among vertebrate GHRs and have been recognized as important in receptor functionality.  The 
Y/FGEFS motif is common to GHRs and replaces the WSXWS motif common to all cytokine 
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receptors (Langenheim et al., 2006).  Consistent with the pattern observed so far, this motif in 
rainbow trout GHR1 appears as FGEFS, which is common for most telesost GHR1s and GHRs. 
(Ellens and Sheridan, 2013).  However, some species display variability between paralogs; in 
Japanese eel, the first position in GHR1 is phenylalanine whereas in GHR2 the first position is 
alanine (cf. Ellens and Sheridan, 2013).  The motif appears to be important for maintaining 
structural integrity of the extracellular domain and signal propagation.  Mutations of this motif in 
humans results in Larone syndrome, a condition of growth hormone insensitivity due to loss of 
GHR function (cf. Langenheim et al., 2006).  Cysteine residues are involved in disulfide bonds 
that affect the conformation of the receptor and impact receptor dimerization, ligand binding, and 
signal transduction (Ellens and Sheridan, 2013).  The presence of 7 conserved cysteines in 
rainbow trout GHR1 contribute to our understanding of GHR divergence.  The pattern emerging 
is that 7 conserved cysteines is the ancestral condition based on sequence information from the 
lamprey (Ellens et al., 2013).  With the advent of teleosts and the FSGD event, type 1 GHRs 
retained the ancestral conditions with some slight variability in the last position, whereas type 2 
GHRs have between 4 and 5 Cys residues (Ellens et al., 2013).    
Also conserved in the extracellular domain are potential N-glycosylation sites which may 
be involved in cell surface targeting.  Five potential sites are present in trout GHR1, which also 
appear in rainbow trout GHR2s; two of these, corresponding to positions 149 and 188 of trout 
GHR1, are conserved in all vertebrates (cf. Ellens and Sheridan, 2013).  A third site, 
corresponding to position 63 of trout GHR1 also is conserved in all fish as well as in frog, turtle, 
and some birds, but is absent  in mammals (cf. Ellens and Sheridan, 2013).   There are four 
regions on GHRs that appear important for hormone binding.  The nature of these regions in 
trout GHR1 are similar to those of other teleost type 1 GHRs, which vary from the corresponding 
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regions in type 2 GHRs (Ellens et al, 2013).  Collectively, the structural features of teleost 
GHR1s and GHR2s results in differences in the conformation of the receptors (Ellens et al., 
2013) that may underlie the observed difference in ligand binding features (Reindl et al., 2009). 
Phosphorylation sites on the intracellular domain mediate signal transduction to a variety 
of effector pathways, including JAK-STAT, ERK, and PI3K-Akt (Kopchick and Andry, 2000; 
Forsyth and Wallis, 2002; Waters et al., 2006).  Although the number of tyrosine residues on 
trout GHR1 and GHR2s are similar, their relative positions vary (cf. Fig 2 and Very et al., 2005).  
Because such differences between the two trout type 2 GHRs result in differential activation of 
signal cascades (Kittilson et al., 2011), it is not unreasonable that similar differences between 
type 1 GHRs and type 2 GHRs would result in differential activation of signaling pathways (Jiao 
et al., 2006; Chen et al., 2011) 
Nutritional state regulated expression of GHR1 mRNAs.  This was evidenced by reduced 
steady-state levels of GHR1 in all of the tissues of rainbow trout examined, including liver, 
adipose, and red and white muscle.  Similar reductions in hepatic GHR1 expression have been 
observed in black sea bream (Deng et al., 2004) and hybrid striped bass (Picha et al., 2008).  
Expression of GHR2 mRNAs in liver also have been reported in several species of fish, 
including rainbow trout, masu salmon, and catfish (Fukada et al., 2004; Small et al., 2006; 
Norbeck et al., 2007; Peterson et al., 2009).  Together, these findings indicate that fasting 
regulates hepatic GHR1s and GHR2s in a similar manner; such widespread diminution of GHR 
expression would explain reduced hepatic sensitivity to GH as well as reduced hepatic IGF-1 
production and growth retardation associated with food deprivation (Uchida et al., 2003; 
Chauvigne et al., 2003; Deng et al., 2004; Fox et al., 2006; Pedroso et al., 2006; Small et al., 
2006; Norbeck et al., 2007).  Interestingly, the pattern of GHR expression differs in among 
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tissues.  In adipose tissue, GHR1 and GHR2b expression is reduced, as shown in this study, 
whereas GHR2a expression is increased (Norbeck et al., 2007).  In muscle, levels if GHR1 
decrease in hybrid striped bass increase (Picha et al., 2008) similar to GHR1 in muscle in 
observed in trout (this study); by contrast, levels of GHR2 increased in muscle of hybrid striped 
bass and tilapia (Picha et al., 2008; Fox et al., 2010).  Such differential regulation of GHRs 
suggested a means by which some actions of GH (e.g., growth promotion; cf. Reindl and 
Sheridan 2012) are reduced whereas other actions (e.g., protein sparing, lipolysis), which would 
be adaptive during periods of food deprivation (cf. Norbeck et al., 2007).  The activation of 
different of GH-mediated responses is possible through differential linkage of GHR subtypes to 
cellular effector pathways.  For example, trout GHR2a preferentially activates STAT, whereas 
GHR2b preferentially activated ERK and Akt (Kittilson et al., 2011).   
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CHAPTER 3: DIFFERENTIAL EFFECTS OF GROWTH HORMONE-FAMILY 
PEPTIDES ON THE EXPRESSION OF IGF-1 AND -2 MRNAS 
Abstract 
Growth hormone (GH) and other hormones in the growth hormone family are responsible 
for a multitude of actions in organisms including feeding, metabolism, reproduction, 
osmoregulation, immune function and behavior.  In this study, we used juvenile (postembryonic) 
rainbow trout to examine the influence of GH family peptides on the expression of IGF-1 and 
IGF-2 mRNAs and to assess the mechanism(s) through which they exert their actions.  Fish were 
implanted with mini osmotic pumps containing GH or saline for 21 days.  Growth hormone was 
found to significantly increase food conversion and growth in both relative length and relative 
weight. Growth hormone significantly increased mRNA levels of IGF-1 and IGF-2 in both liver 
and muscle compared to levels observed in saline-implanted fish.  Western blot analysis showed 
that both GH and prolactin (PRL) caused an increase of phosphorylation of JAK, STAT, ERK, 
and AKT.  The direct effects of GH, PRL, and somatolactin (SL) were assessed on isolated 
hepatocytes incubated in vitro. Growth hormone stimulated expression of IGF-1 and IGF-2 
mRNAs in a concentration- and time-related manner. Growth hormone was more efficacious in 
stimulating expression of IGF-2 than IGF-1 expression. The ERK pathway inhibitor, U0126, and 
the PI3K/Akt pathway inhibitor, LY294002, blocked GH-stimulated IGF-1 and IGF-2 
expression. Prolactin had slight but significant effects on the expression of IGF-1 and IGF-2. 
Prolactin-stimulated expression of IGF mRNAs also was blocked by U0126 and LY294002.  
Somatolactin had no effect on the expression of either IGF-1 or IGF-2 mRNA. These findings 
indicate that GH stimulates IGF-2 expression to a greater extent than IGF-1 expression and PRL 
stimulates both IGFs equally, both of these facts support a role of IGF-2 in postembryonic 
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growth of fish. These findings also indicate that GH- and PRL- stimulated IGF-1 and IGF-2 
expression involves activation of the ERK, PI3K/Akt, and JAK2-STAT5 signaling pathways. All 
of this information taken together helps understand the complex nature of organismal growth as 
well as providing a possible mechanism for the myriad of actions of GH family hormones. 
Introduction 
Growth hormone (GH), prolactin (PRL), and somatolactin (SL) all belong to the larger 
somatotropin family of hormones and all share similar structure among fishes (Forsyth and 
Wallis 2002).  These hormones also share similar type I cytokine receptors with a single 
membrane-spanning domain (Kossiakoff and Vos 1999; Wallis 1992). While these hormones 
have many similarities they have been shown to have both similar and unique effects. Growth 
hormone has been shown to regulate many processes in vertebrates including feeding, 
metabolism, reproduction, osmoregulation, immune function and behavior. The most studied 
actions of GH involve the promotion of organismal growth (Bjornsson et al., 2004; Forsyth and 
Wallis 2002; Moller and Jorgensen 2009; Norbeck et al., 2007; Norrelund 2005). Prolactin has 
shown to have a wide array of functions including osmoregulation (Maetz 1970), growth 
(Rynikova et al., 1988), metabolism (Vilalba et al., 1991), behavior (Blum and Fiedler 1965), 
reproduction (Dunaif et al., 1982), and immunity (Nagy et al., 1983). The most recently 
discovered of these hormones is SL. The main physiological function of SL is still debated but 
SLs are involved in reproductive maturation (Johnson et al., 1997), acid–base balance (Kakizawa 
et al., 1996), background adaptation (Kakizawa et al., 1995), immune function (Calduch-Giner et 
al., 1998), energy mobilization and stress (Rand-Weaver et al., 1993), lipid metabolism and 
pigmentation (Zhu and Thomas 1997; Fukamachi et al., 2009), and the regulation of 
chromatophores (Zhu and Thomas 1997). While all the hormones in this family share many 
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functions, this study will focus on these hormones control of growth through insulin-like growth 
factors 1 and 2 (IGF-1 and IGF-2). 
The actions of GH are initiated by binding to GHRs present on the plasma membrane of 
target cells. GHRs belong to the class I cytokine receptor family, which consists of a single 
transmembrane protein containing an extracellular ligand binding domain and an intracellular 
signal transduction domain (Argetsinger and Carter-Su 1996). PRL and SL also work through 
similar mechanisms since they also have similar evolutionarily conserved receptors (Kelly et al., 
1991). GHRs have been characterized from over 100 species, including some 25 species of fish. 
Fish possess multiple GHRs that appear to have derived from several genome duplication events 
over the course of their evolution (Fukamachi and Meyer 2007; Reindl et al., 2009).   
While GHRs are most abundant in the liver of mammals and fish, they are expressed 
widely in many tissues, observations that are consistent with the pleiotropic actions of GH 
(Kopchick and Andry 2000; Very et al., 2005; Walock et al., 2014). PRLR also share similar 
diverse distributions also mirroring its pleotropic actions (Nagano and Kelly 1994).   
In mammals, GH binding to dimerized GHRs is followed by recruitment of Janus kinase 
2 (JAK2) to the receptor complex and the rapid phosphorylation of GHR and JAK2; signal is 
propagated by activation of several other proteins and pathways, including transducer and 
activator of transcription 5 (STAT5) as well as the extracellular signal-regulated kinase (ERK) 
and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) pathways (Piwien-Pilipuk et al., 
2002). Many of these similar signaling elements are also found to be activated by PRLR 
including JAK2 (Campbell et al., 1994) and STAT5 (Pezet et al., 1997).  The GH-IGF-1 system 
has been well studied in mammals and fish, and the main elements appear to be highly conserved 
(Bulter and LeRoith 2001; Reinecke et al., 2005). Circulating GH stimulates the synthesis and 
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secretion of IGF-1 from the liver, and IGF-1, in turn, stimulates cell growth and differentiation in 
a variety of target tissues via distinct IGF-1 receptors (IGFR1) (Laviola et al., 2007; Wood et al., 
2005). GH has also been shown to act in stimulating IGF-2 secretion from the liver (Shamblot et 
al., 1995; Pierce et al., 2010). The availability and actions of GH and IGF-1 are influenced by 
GH binding proteins and IGF binding protein (IGFBPs), respectively (Bauman et al., 1988; Duan 
and Xu 2005). The GH-IGF-1 system of fish is particularly complex because of the existence of 
multiple isoforms of GHs, GHRs, IGFs, IGFBPs, and IGFRs (Reinecke et al., 2005). 
IGF-1 and IGF-2 are mitogenic peptides that control vertebrate growth (Humbel 1990; 
Jones and Clemmons 1995; Reinecke and Collet 1998).  Both IGFs bind a common receptor 
IGFR1 and both have their activities modulated by multiple IGFBPS. In addition, local 
production of IGF-1 is important, and GH and IGFBPs have direct, non-IGF-1 dependent effects 
(Bulter and LeRoith 2001; Duan and Xu 2005; Wood et al., 2005). Insulin-like growth factor-1 
from the liver is the primary mediator of GH-dependent growth. Insulin-like growth factor-2 is 
highly expressed during embryogenesis and stimulates embryonic growth (Jones and Clemmons 
1995; Reinecke and Collet 1998; Wood et al., 2005; White et al., 2009). During this time IGF-1 
expression is low and increases later in post-natal growth. Studies have shown that IGF-2 is not 
strongly stimulated by GH in postnatal animals (Humbel 1990; Holly 1998). However, recent 
studies have shown in many species including salmonids, sea bream, carp, catfish, eels, 
rabbitfish, sea bass, hybrid striped bass, tilapia, and dogfish, that, in fish, GH stimulates liver 
IGF-2 expression, unlike in mammals (Shamblott et al., 1995; Tse et al., 2002; Peterson et al., 
2004; Carnevali et al., 2005; Ayson et al., 2007; Terova et al., 2007; Moriyama et al., 2008; 
Picha et al., 2008; Eppler et al., 2010). This suggests that IGF-2 may also be a major mediator of 
postnatal growth in fish as opposed to the current understanding of mammalian growth. Despite 
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this research, more work is needed to fully understand GH, PRL, and SL in their relationship to 
growth. In this study, we used rainbow trout as a model to examine the mechanism of GH, PRL, 
and SL action on IGF-1 and IGF-2 expression in fish.  Specifically we tested the hypothesis that 
the ERK, PI3K/AKT, and JAK2-STAT5 signal pathways mediate GH and PRL stimulated 
expression of IGF-1 and IGF-2. 
Materials and methods 
Experimental animals and conditions 
Juvenile rainbow trout of both sexes (ca. 1 year of age) were obtained from Dakota Trout 
Ranch (Carrington, ND). The animals were transported to North Dakota State University, where 
they were maintained in well-aerated, 800-L circular tanks supplied with recirculated (10% 
make-up volume per day) dechlorinated municipal water at 14°C under a 12:12 hour light: dark 
photoperiod. Fish were fed twice daily to satiety with AquaMax Grower (PMI Nutrition 
International, Brentwood, MO, USA) semi-floating trout grower, except 24–36 h prior to 
commencing experiments in order to prevent any postprandial responses that feeding may cause. 
Animals were acclimated to laboratory conditions for at least 4 weeks prior to experimentation. 
Implantation experiment 
The effects of growth hormone (GH) on the patterns of IGF-1 andIGF-2 mRNA 
expression were evaluated by implanting fish with Alzet® mini-osmotic pumps (Alza; Palo Alto, 
CA) containing either 0.75% (w/v) NaCl (control) or 200 ng/ml ovine growth hormone (obtained 
from NIH).  Mini-pump flow rate was established to be 0.135 μl h-1, which at 14°C should 
provide sustained release for 29 days.  Fish were first anesthetized with 0.05% (v/v) 2-
phenoxyethanol, and their body length and mass were determined.  Mini-pumps were inserted 
into the peritoneal cavity through a 1.0-cm incision that was made 0.5 cm right of the ventral 
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midline and 2.0 cm in front of the pelvic fins. The incision was closed with two stitches and 
antibiotic ointment (Neosporin®) was applied topically to the incision. Fish were placed into 
100-L tanks (one tank for each treatment group) under the same conditions as acclimation, 
except that each tank was treated with 250 mg erythromycin with no water turnover for 30 min 
while supplemented with pure oxygen and feeding was suspended.  
Seventy-two hours after tagging and transfer, fish were fed twice daily at a ration of 2% 
of their initial body mass per feeding and continued for the duration of the experiment, except 
24h prior to sampling. One hour after feeding excess food was collected and dried in an oven 
until moisture was removed, and weighed in order to calculate food intake (7% increase to dried 
food was added to adjust for moisture content).  Fish were anesthetized by immersion in 0.05% 
(vol/vol) 2-phenoxyethanol and euthanized by transaction of the spinal cord. Skeletal muscle and 
liver tissues were collected 21 days after implantation and tissues were immediately frozen on 
dry ice for later analyses. 
 Hepatocyte isolation 
Fish were anesthetized by immersion in 0.05% (vol/vol) 2-phenoxyethanol and 
euthanized by transaction of the spinal cord. Hepatocytes were isolated by the in situ perfusion 
method of (Mommsen et al., 1994). The isolated cells were allowed to recover in incubation 
medium [in mM: 136.9 NaCl, 5.4 KCl, 0.81 MgSO4, 0.44 KH2PO4, 0.33 Na2HPO4, 10 HEPES, 5 
NaHCO3, and 1.5 CaCl2, pH 7.6, with 2% (wt/vol) defatted BSA, 3 mM glucose, 2 ml Gibco 
MEM amino acid mix (50×)/100 ml, and 1 ml Gibco nonessential amino acid mix (100×)/100 
ml] for 3 h at 14°C with gyratory shaking (100 rpm) under 100% O2. The viability of the cells 
was assessed by trypan blue dye exclusion and ranged between 93–97% for all experiments. 
After the recovery period, hepatocytes were collected by centrifugation (500 g for 3 min at 14°C) 
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and resuspended in incubation medium to a final concentration of 2 × 106 cells/ml, and 
aliquotted into 24-well plates (2 × 106 cells/well). Cells were incubated in medium alone 
(control) or in medium containing the designated hormone treatment under the same conditions 
as those used for recovery (14°C with gyratory shaking at 100 rpm under 100% O2) for various 
times as specified in the figure legends. In combination experiments involving inhibitors, the 
specific inhibitor was added 2 h prior to hormone treatment at concentrations shown maximally 
effective by the manufacturer and/or which were used previously (Reindl et al., 2011). 
Incubations were stopped by centrifugation (500 g for 3 min at 14°C); cell pellets were either 
prepared immediately for Western blot analysis or resuspended in 0.5 ml Tri Reagent (Molecular 
Research Center, Cincinnati, OH), frozen on dry ice, and stored at −80°C for later extraction of 
RNA. The hepatocytes used in replicates for a given experiment were obtained by pooling 
hepatocytes from individual fish and dividing into replicates. 
RNA extraction and analysis 
Total RNA was extracted using TRI-Reagent® (Molecular Research Center, Inc., 
Cincinnati, OH, USA) as specified by the manufacturer’s protocol. Each RNA pellet was 
redissolved in 35–200 μl RNase-free deionized water and quantified by NanoDrop1000 
spectrophotometry (A260) (Thermo Scientific, West Palm Beach, FL, USA). RNA samples were 
then stored at −80 °C until further analysis.  
mRNA was reverse transcribed in 5 μl reactions using 150 ng total RNA and 
AffinityScript QPCR cDNA Synthesis kit reagents (Master Mix, random primers, oligo-dT 
primers, and reverse transcriptase with block) according to the manufacturer’s protocol 
(Stratagene, La Jolla, CA, USA). Reactions without reverse transcriptase were included as 
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negative controls to exclude the possibility of contamination with genomic DNA; no 
amplification was detected in negative controls. 
Levels of IGF-1 and IGF-2 mRNAs were determined by quantitative real-time PCR as 
described previously (Malkuch et al., 2008). Briefly, real-time reactions were carried out for 
samples, standards, and no-template controls in multiplex reactions with IGF-1or IGF-2 and β-
actin. cDNA standards were generated using  IGF-1 and IGF-2 gene-specific primers, the PCR 
products were cloned into the pGEM-T Easy Vector, and the sequences were verified. Reactions 
contained 2 μl cDNA from the reverse transcription reactions, 5 μl Brilliant® II QPCR Master 
Mix (Stratagene), 1 μl of each 150 nM gene-specific probes [IGF1: 5′-FAM- 
AAAGCCTCTCTCTCCA-MGBNFQ -3′ (150 nM); IGF2: 5′-FAM- 
AGATCATTCCCATGGTGC-MGBNFQ -3′ (150 nM); β-actin: 5′-VIC-
TGCTTGCTGATCCACAT-MGBNFQ -3′ (150 nM)], 0.5 μl of gene-specific forward [IGF1: 5’-
GTGGACACGCTGCAGTTTGT-3’ (600 nM); IGF2: 5′-ACGTGTCGGCCACCTCTCTA-3′ 
(600 nM); β-actin: 5′-GGCTTCTCTCTCCACCTTCCA-3′ (900 nM)] and reverse primers 
[IGF1: 5’-CATACCCCGTTGGTTTACTGAAA-3’ (600 nM); IGF2: 5′-
TGGGACATCCTGTTTGATTGTG-3′ (600 nM); β-actin: 5′-
AGGGACCAGACTGTCGTAACTC-3′ (900 nM)], and 0.15 μl reference dye (Stratagene, 
Agilent Technologies). Cycling parameters were set as follows: 95 °C for 10 min and 45 cycles 
of 95 °C for 30 s and 58 °C for 1 min. Cross reaction was assessed by substituting alternate 
primer/probe sets in assays for each standard; no amplification was observed under these 
conditions. Sample copy number was calculated from the threshold cycle number (CT) and 
relating CT to a gene-specific standard curve, followed by normalization to β-actin. 
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Western blotting 
Tissues were homogenized in 300 μl 1x cell lysis buffer (Cell Signaling Technology, 
Beverly, MA) with 1 mM PMSF, 1x protease inhibitor (Calbiochem, San Diego, CA, USA), and 
1x phosphatase inhibitor (G-Biosciences, St. Louis, MO, USA). The homogenate was incubated 
on ice for 5 min then centrifuged at 16,000g for 10 min at 4 °C. The protein concentration of the 
supernatant was determined by the Bio-Rad (Hercules, CA, USA) dye-binding method for 
microplates. Proteins (typically 50 μg) and molecular weight marker (Cell Signaling Technology, 
Beverly, MA; Catalog No. 7727) were separated by SDS–PAGE (7.5% running gel) and 
transferred to 0.45 μm nitrocellulose (Bio-Rad Laboratories) for western blot analysis as 
described by Reindl et al. (2011). Membranes were washed and visualized with 
chemiluminescence according to the manufacturer’s instructions (GE Healthcare, 
Buckinghamshire, UK); chemiluminescence was detected directly and the bands quantified with 
a FluorChem FC2 imager (Alpha Innotech Corp, San Leandro, CA, USA). The abundance of 
phosphorylated ERK 1/2, Akt, JAK2, and STAT5 was normalized to total ERK 1/2, Akt, JAK2, 
STAT5, and β-actin, respectively. All antisera were obtained from Cell Signaling Technology 
(Beverly, MA); antisera for ERK 1/2, Akt, JAK2, and STAT5 were validated for the detection of 
signaling elements in rainbow trout previously (Reindl et al., 2011). 
Data analysis 
Statistical differences were estimated by one-way or two-way ANOVA, as appropriate. 
In all cases, main effects were significant, and no significant interactions were observed between 
main effects in two-way ANOVAs. Pairwise comparisons of simple effects were assessed by 
Duncan's multiple range test; statistical notations on the faces of the figures reflect such 
comparisons. A probability level of 0.05 was used to indicate significance. All statistics were 
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performed using SigmaStat version 1.0 (SPSS, Chicago, IL), and graphs were constructed with 
SigmaPlot version 8.0 (SPSS). Quantitative data are expressed as means ± SEM. 
Results 
In vivo effects of GH on food intake, food conversion, and growth 
Although food intake was similar between saline- and GH-implanted fish, food 
conversion was 37% higher in GH treated animals compared to controls (Fig. 7). Growth 
Hormone implantation resulted in significant growth, in which the most pronounced effect was 
on body length.  Relative growth in mass was increased by 42%, whereas relative growth in 
length was increased by 140% in GH treated fish compared to controls (Fig.7). 
In vivo effects of GH on IGF expression 
GH implantation increased steady-state levels of mRNAs encoding both IGF-1 and IGF-2 
in liver and skeletal muscle, with IGF-1 levels being stimulated to 133% and 169% of controls in 
skeletal muscle and liver accordingly and IGF-2 levels being stimulated to 171% and 226% of 
controls in skeletal muscle and liver accordingly (Fig. 8).  Growth hormone stimulated IGF-2 
mRNA expression to a greater extent than IGF-1 mRNA expression in both skeletal muscle and 
liver. Liver was also more sensitive to GH stimulation showing higher stimulated expression 
levels of both IGF-1 and IGF-2 (Fig. 8). 
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Fig. 7. Average daily food intake and food conversion ratio (A) and changes in relative growth 
via both relative length and weight of rainbow trout implanted with ovine growth hormone (GH) 
or 0.75% saline over a 21-day trial (B). Food conversion efficiency was calculated as (body wet 
mass gain) / (dry weight food intake per fish). Relative weight and length were calculated as 
(100*[final body mass (or length) - initial body mass (or length)]) / [initial body mass (or 
length)]. Data are presented as % control from controls and expressed as means ± SEM (n=6). 
For a given treatment, groups with different letters are significantly (P<0.05) different. 
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Fig. 8. Changes in the expression of insulin-like growth factor subtype (IGF-1 and IGF-2) 
mRNA in the liver (A) and muscle (B) of rainbow trout associated with GH implantation. Data 
are presented as % control from controls and expressed as means ± SEM (n=6). For a particular 
tissue, letters denote significant (P<0.05) differences for a given subtype across treatments; * 
denotes a difference in subtypes within a given treatment. 
 
In vitro of GH and PRL on JAK, STAT, ERK and AKT phosphorylation 
The roles of GH and PRL on JAK, STAT, ERK, and AKT phosphorylation were 
examined in vitro using isolated hepatocytes. The activation of these cell signaling pathways was 
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studied on lysates from hepatocytes probed with phosphospecific and control antibodies. 
Treatment of hepatocytes in vitro with GH activated JAK, STAT, ERK, and AKT (Fig. 9). GH 
activated JAK most effectively to 193% of control. GH activation of STAT, ERK, and AKT 
were 146%, 187%, and 162% respectively (Fig. 9). Treatment of hepatocytes in vitro with PRL 
also activated JAK, STAT, ERK, and AKT (Fig. 10). PRL activated ERK most effectively to 
168% of controls. PRL activation of JAK, STAT, and AKT were 147%, 134%, and 156% 
respectively (Fig. 10). 
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Fig. 9. Effects of growth hormone (GH) on the abundance of phosphorylated Janus kinase 2 
(JAK2), signal transducer and activator of transcription 5 (STAT5), protein kinase B (Akt), and 
extracellular signal-regulated kinase (ERK) in isolated hepatocytes of rainbow trout. A, B, C, D: 
phosphorylation of JAK2, STAT5, Akt, and ERK respectively, in cells incubated with100 ng/ml 
GH for 30 min (control is 0 ng/ml GH).  Cell lysates were separated by SDS-PAGE followed by 
Western immunoblotting, and the blots were quantified with a FluorChem imager.  The 
abundance of phosphorylated JAK2, STAT5, Akt, and ERK was normalized to total JAK2, 
STAT5, Akt, and ERK respectively.  Data are presented as means + SEM (n=6). Groups with 
different letters are significantly (p < 0.05) different. 
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Fig. 10. Effects of prolactin (PRL) on the abundance of phosphorylated Janus kinase 2 (JAK2), 
signal transducer and activator of transcription 5 (STAT5), protein kinase B (Akt), and 
extracellular signal-regulated kinase (ERK) in isolated hepatocytes of rainbow trout. A, B, C, D: 
phosphorylation of JAK2, STAT5, Akt, and ERK respectively, in cells incubated with100 ng/ml 
PRL for 30 min (control is 0 ng/ml PRL).  Cell lysates were separated by SDS-PAGE followed 
by Western immunoblotting, and the blots were quantified with a FluorChem imager.  The 
abundance of phosphorylated JAK2, STAT5, Akt, and ERK was normalized to total JAK2, 
STAT5, Akt, and ERK respectively.  Data are presented as means + SEM (n=6). Groups with 
different letters are significantly (p < 0.05) different. 
 
In vitro effects of GH, PRL, and SL on IGF expression 
The roles of GH, PRL, and SL on IGF expression were examined in vitro using isolated 
hepatocytes. Growth hormone directly stimulated the expression of IGF-1 and IGF-2 mRNAs in 
isolated hepatocytes in a time-dependent and concentration-related manner. Maximum 
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stimulation occurred after 6 h treatment with IGF-1 expression at 178% and IGF-2 at 243% of 
controls (Fig. 11). Growth hormone was significantly more efficacious at stimulating IGF-2 over 
IGF-1(Fig. 11). Prolactin had a similar expression pattern to GH, stimulating IGF-1 and IGF-2 
mRNAs in isolated hepatocytes in a time- and concentration-dependent manner. Maximum 
stimulation occurred after 6 h treatment with IGF-1 expression at 139% and IGF-2 at 146% of 
controls (Fig. 11).  Unlike GH, PRL stimulated both IGF-1 and IGF-2 to similar levels (Fig. 11). 
Somatolactin treatment had no effect on either IGF-1 or IGF-2 mRNA expression (Fig. 11). 
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Fig. 11. Effects of growth hormone (GH), prolactin (PRL), and somatolactin (SL) on the 
expression of insulin-like growth factor subtype (IGF-1 and IGF-2) mRNA in isolated 
hepatocytes of rainbow trout. A, C, E: time dependent IGF-1 and IGF-2 mRNA expression in 
cells incubated for varying times with 100 ng/ml GH, PRL, or, SL respectively. B, D, F: dose 
dependent IGF-1 and IGF-2 mRNA expression in cells incubated for 6 hours in varying 
concentrations of GH, PRL or, SL respectively. Data are presented as % control from controls 
and expressed as means ± SEM (n=6). For a particular hormone, letters denote significant 
(P<0.05) differences for a given subtype across treatments; * denotes a difference in subtypes 
within a given treatment. 
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Linkage of the ERK, PI3K/AKT, and JAK/STAT signaling pathways to GH-stimulated 
IGF-1 and IGF-2 expression 
The roles of the ERK, PI3K/AKT, and JAK/STAT signaling pathways on GH-, PRL- , 
and SL-stimulated IGF-1 and IGF-2 expression in isolated hepatocytes was investigated using 
inhibitors specific to these pathways. Initial experiments examined the effects of inhibitors alone 
and in combination with GH, PRL, and SL. As previously observed (Fig. 11), GH and PRL 
increased steady-state levels of IGF-1 and IGF-2 mRNA in isolated hepatocytes incubated in 
vitro while SL still had no effect on IGF expression. Incubation with any inhibitor alone had no 
effect on IGF-1 and IGF-2 mRNA expression. Blockade of the ERK pathway with the MEK 
inhibitor U0126 (U) partially inhibited GH and PRL-stimulated IGF-1 and IGF-2 expression 
(Fig. 12).  Blockade of the PI3K/AKT pathway with a PI3K inhibitor LY294002 (LY) or AKT 
inhibitor 1L6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-
glycerocarbonate (CARB) partially inhibited GH- and PRL-stimulated IGF-1and IGF-2 
expression; for GH-stimulated IGF expression, the effect of PI3K inhibition was greater than 
AKT inhibition (Fig. 12). Inhibition of STAT5 with N’-((4-oxo-4H-chromen-3-yl)methylene) 
nicotinohydrazide (NICO) partially blocked GH- and PRL- stimulated IGF-1 and IGF-2 
expression (Fig. 12) to levels similar to ERK and AKT inhibition.   Inhibition of JAK with 
1,2,3,4,5,6-hexabromocyclohexane  (HEX) abolished GH- and PRL-stimulated IGF-1 and IGF-2 
expression  to control levels(Fig. 12). 
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Fig. 12. Effects of signaling element blockades on growth hormone (GH), Prolactin (PRL), and 
somatolactin (SL)-stimulated expression of insulin-like growth factor subtype (IGF-1 and IGF-2) 
mRNA in isolated hepatocytes of rainbow trout.  Hepatocytes were preincubated for 2 h with or 
without specific inhibitors for the following signaling elements: MEK (10 μM U0126=MEK-I),  
PI3K (10 μM LY294002=PI3K-I), Akt (10 μM Carb=Akt-I.), JAK2 (10 μM Hex=JAK-I), 
STAT5 (10 μM NICO=STAT-I); and in the absence or presence of GH(A), PRL(B) or, SL(C) at 
100 ng/ml for 6 h (control is 0 ng/ml GH, PRL or, SL); after which time, cells were treated with 
100 ng/ml GH, PRL or, SL for 6 h (control is 0 ng/ml GH, PRL or, SL). Data are presented as % 
control from controls and expressed as means ± SEM (n=6). For a given hormone, groups with 
different letters are significantly (p < 0.05) different across treatments; * denotes a difference in 
subtypes within a given treatment. 
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Discussion 
The results of this study indicate that GH and PRL stimulate IGF-1 and IGF-2 
expression. This expression is mediated through the ERK, PI3K/Akt, and JAK2-STAT5 
signaling pathways. These findings support our starting hypothesis that the ERK, PI3K/AKT, 
and JAK2-STAT5 signal pathways mediate GH and PRL stimulated expression of IGF-1 and 
IGF-2. These findings provide new insight into the mechanisms that underlie organismal growth 
as well as coordinating GH and PRLs multitude of actions. 
GH was previously shown to stimulate hepatic IGF-1 expression and to increase levels of 
IGF-1 in the plasma of several species of fish, including carp, coho salmon, rainbow trout, and 
tilapia (Very et al., 2008;Wood et al., 2005). GH has also been shown to increase IGF-1 
expression in rainbow trout hepatocytes (Reindl et al., 2011) and increase IGF-2 expression in 
multiple species of fish including salmonids (Shamblot et al., 1995; Pierce et al., 2010). The 
present results confirm the effects of GH on IGF-1 and IGF-2 expression in isolated trout 
hepatocytes incubated in vitro and in vivo in both liver and muscle, and support our starting 
hypothesis.  PRL has also been shown to increase IGF-1 levels in rats (Hill et al., 1977) and IGF-
2 levels in bats (Viengchareun et al., 2008). Our results also confirm the effects of PRL on IGF-1 
and IGF-2 expression in isolated trout hepatocytes incubated in vitro, which supports our starting 
hypothesis. SL was shown to have no effects on either IGF-1 or IGF-2 expression supporting our 
original hypothesis that SL would have no effect on IGF-1 and IGF-2 expression.  This is 
supported by the fact that SL is less involved in growth regulation than the other somatotropins. 
These findings confirm the mechanisms through which GH and PRL exerts their growth-
promoting actions and provide insight into the signaling pathways that may underlie the many 
other actions of GH and PRL in fish. 
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The role of the ERK pathway in GH and PRL-stimulated IGF-1 and IGF-2 production 
was supported by several observations. GH and PRL directly induced the phosphorylation of 
ERK1/2 in trout hepatocytes. Blockade of the ERK pathway with U0126 also partially inhibited 
hepatic expression of IGF-1 and IGF-2. These findings are consistent with those in mammals in 
which GH-induced activation of the ERK pathway and the activation of IGF-1 transcription 
(Argetsinger and Carter-Su 1996; Kopchick and Andry 2000; Piwien-Pilipuk et al., 2002), as 
well as with PRL stimulated ERK phosphorylation in human endometrium natural killer cells 
(Gubbay et al., 2002). Because U0126 only partially blocked GH-induced IGF-1 production in 
trout hepatocytes, mechanisms other than the ERK pathway could be operating to influence the 
growth-promoting actions of GH. 
The role of the PI3K/Akt pathway in GH and PRL-stimulated IGF-1 and IGF-2 
production also was supported by several observations. GH and PRL directly induced the 
phosphorylation of Akt in trout hepatocytes. Blockade of the PI3K/Akt pathway with the 
selective PI3K inhibitor LY294002 partially inhibited hepatic expression of IGF-1 and IGF-2. 
For GH-stimulated IGF expression, the effect of PI3K inhibition was greater than Akt inhibition, 
suggesting the involvement of a downstream target of PI3K other than Akt. Collectively, these 
findings are consistent with those in mammals in which GH-induced activation of the PI3K/Akt 
pathway and the activation of IGF-1 transcription (Argetsinger and Carter-Su 1996; Kopchick 
and Andry 2000; Piwien-Pilipuk et al., 2002) as well with PRL stimulation of PI3K/Akt pathway 
in human breast cancer lines (Richert et al., 2001). As was the case with ERK blockade of GH- 
and PRL-induced IGF-1 and IGF-2 production in trout hepatocytes, PI3K/Akt blockade was not 
complete, which suggested that yet other pathways could be operating to influence the growth-
promoting actions of GH. 
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The role of the JAK-STAT pathway in GH-stimulated IGF-1 production also was 
supported by several observations. GH and PRL directly induced the phosphorylation of JAK2 
and STAT5 in trout hepatocytes. Blockade of the JAK-STAT pathway with JAK2 specific 
inhibitor Hex completely inhibited hepatic expression of IGF-1 and IGF-2. That GH-stimulated 
IGF-1 production was dependent, at least in part, on STAT5 was confirmed by the observation 
that the STAT5-specific inhibitor NICO partially blocked GH- and PRL-stimulated IGF-1 and 
IGF-2 expression. Together, these findings are consistent with those in mammals that 
demonstrated the role of JAK2 in the activation of STAT5 and the subsequent role of STAT5 in 
stimulating IGF-1 transcription (Argetsinger and Carter-Su 1996; Kopchick and Andry 2000; 
Piwien-Pilipuk et al., 2002) as well as with PRL stimulation of JAK2 and STAT5 (Campbell et 
al., 1994; Pezet et al., 1997). By observing and combining the roles of each signaling pathway 
studied, we were able to come up with a model summarizing the mechanisms behind the actions 
of GH and PRL (Fig. 13). Rainbow trout are known to possess multiple differentially regulated 
GHR receptors (Very et al., 2005; Walock et al., 2014) as well as a PRLR (Rouzic et al., 2001). 
For this study individual GHRs or GHR/PRLR were not studied for their relationship to 
downstream signaling, so we can’t assume which receptor is being bound. Knowing that GHRs 
have differential expression and are differentially regulated (Very et al., 2005; Walock et al., 
2014) would make isolating the binding and possible differential effects of each individual 
receptor type an interesting possible avenue of future studies. 
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Fig. 13. Model of signaling events associated with GH- and PRL-stimulated IGF-1 and IGF-2 
expression in hepatocytes of rainbow trout. JAK2 is activated following binding of GH and PRL 
to the GH receptor (GHR). The activation ofJAK2 is important for the continuation of 
downstream signaling through ERK, PI3K/Akt, and STAT5, all of which mediate the actions of 
GH and PRL on IGF-1and IGF-2 expression. 
 
In summary we found that somatotropin family hormones are able to stimulate growth 
via both IGF-1 and IGF-2. GH was able to stimulate IGF-1 and IGF-2 expression both in vivo in 
liver and muscle and well as in in vitro in isolated hepatocytes. PRL was able to stimulate IGF-1 
and IGF-2 expression in vitro in isolated hepatocytes, while SL was found to have no effect on 
IGF-1or IGF-2 expression. Specifically, GH and PRL stimulated IGF-1 and IGF-2 expression in 
a time and dose dependent manner. This effect was found to be elicited though the ERK, 
PI3K/Akt, and JAK2-STAT5 signaling pathways. The fact that the GH and PRL stimulated IGF 
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expression is mediated through multiple signaling pathways illustrates the possibility of multiple 
ways to differentially regulate GH and PRLs many actions including feeding, metabolism, 
reproduction, osmoregulation, immune function and behavior, organismal growth (Bjornsson et 
al., 2004; Forsyth and Wallis 2002; Moller and Jorgensen 2009; Norbeck et al., 2007; Norrelund 
2005; Maetz 1970; Rynikova et al., 1988; Vilalba et al., 1991; Blum and Fiedler 1965; Dunaif et 
al., 1982; Nagy et al., 1983).These multiple signaling pathways also give possible ways for the 
cells in an organism to adjust to changes in its environment. 
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CHAPTER 4: THE ROLE OF NUTRITIONAL STATE AND SERUM TREATMENT IN 
GROWTH HORMONE MEDIATED INSULIN-LIKE GROWTH FACTOR AND 
GROWTH HORMONE RECEPTOR EXPRESSION 
Abstract 
Growth hormone (GH) regulates a wide array of actions including growth, metabolism, 
and lipolysis. These disparate actions often take place in the same tissues but are associated with 
different nutritional availability such as growth in times of plenty and lipolysis in times of 
fasting.  In this study, we isolated hepatocytes from both fed and fasted rainbow trout 
(Oncorhynchus mykiss)  to test the role of nutritional state on the actions of GH including 
insulin-like growth factor (IGF) and growth hormone receptor (GHR) expression and which 
signaling pathways GH is working through. Additionally we tested the role of serum in changing 
cells responsiveness to GH by pretreating these cells with 10% serum from blood of fish either 
fed or fasted. Our hypothesis is that the growth promoting actions of GH, including increased 
IGF expression, will only be observed in fed fish and that blood serum will mediate this change 
in cell responsiveness.  As expected, GH-stimulated IGF expression was only observed in cells 
from fed fish and not those from fasted fish. This action was found to be through the ERK, 
JAK/STAT, and PI3K/Akt signaling pathways because inhibiting those pathways blocked GH-
stimulated IGF expression. Similar results were not observed with GHR expression; nutritional 
state was observed to have minimal effect on GH-stimulated GHR expression. Serum was found 
to change cells responsiveness to GH in regards to IGF but not GHR expression. While GH was 
unable to stimulate IGF expression in fasted cells, pretreatment of these fasted cells with serum 
from fed cells allowed these cells to change responsiveness to GH, showing an increase in GH-
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stimulated IGF expression as seen in fed cells. These findings support the role of nutritional state 
and more specifically serum in regulating the disparate actions of GH. 
Introduction 
Growth hormone (GH) is a widely studied hormone with a wide array of actions 
including but not limited to growth, feeding, metabolism, reproduction, osmoregulation, immune 
function and behavior (Bjornsson et al., 2004; Forsyth and Wallis 2002; Moller and Jorgensen 
2009; Norbeck et al., 2007; Norrelund 2005). Growth hormone is a part of a wider somatotropin 
family of hormones including Somatolactin (SL) and Prolactin (PRL) (Kossiakoff and Vos 1999; 
Wallis 1992). The main growth regulation action of GH occurs primarily through the GH 
insulin-like growth factor (IGF) pathway. In short, GH released from the pituitary circulates and 
stimulates IGF production primarily in the liver and muscle which then goes on to promote 
organismal growth (LeRoith et al., 2001). This GH-stimulated IGF expression is done through 
the JAK–STAT, PI3K–Akt, and ERK signaling pathways (Reindl et al., 2011). While growth is 
primarily associated with times of feeding and nutritional availability, many other actions of GH 
are not; more are associated with fasting such as lipolysis (Sheridan 1994; Bergan et al., 2013). 
These disparate actions suggest that cells are modulated to perform both actions. 
Fasting is known to play a large role in many different aspects of the GH IGF pathways. 
During times of fasting, rainbow trout first demonstrate decreases in weight and condition 
(Norbeck et al., 2007; Sheridan and Mommsen, 1991).  This decrease in growth is observed 
despite the fact that fasting causes an increase in GH plasma levels in many species (Gomez-
Requeni et al., 2005; Norbeck et al., 2007; Picha et al., 2008; Reinecke, 2010). Fasting also leads 
to other changes in plasma including decreased levels of insulin and IGF-1 (Gomez-Requeni et 
al., 2005; Norbeck et al., 2007). Fasting has also been shown to decrease hepatic growth 
 91 
hormone receptor (GHR) levels (Small et al., 2006; Norbeck et al., 2007) while causing increase 
in GHR levels in muscle (Pierce et al., 2007) and in adipose tissue (Norbeck et al., 2007). These 
changes taken together suggest that the programing and sensitivity of cells to GH changes in 
different nutritional states and depend on the type of cell. 
While much is known about the actions of GH and their signaling pathways (Waters et 
al., 2006), much more is still unknown about the growth promoting actions of GH in differing 
nutritional states and how this differs from the lipolytic actions of GH (Bergan et at. 2015). In 
this study, we used hepatocytes isolated from continuously fed and 4 week fasted rainbow trout 
(Oncorhynchus mykiss) as a model to study the growth-related actions of GH including IGF 
expression and GHR expression. In addition, serum from each of these groups of fish was 
isolated and used to treat cells to see if the serum might be the mechanism that accounts for the 
disparate actions of GH across different nutritional states. My hypothesis is that the growth 
promoting actions of GH, including increased IGF-1 and IGF-2 expression will only be observed 
in fish fed continuously and that the nutritional state of the blood serum will program cells to 
respond to GH by either allowing or inhibiting these growth promoting actions.                                 
Materials and methods 
Materials 
All chemicals and reagents used were purchased from Sigma (St. Louis, MO, USA) 
unless stated otherwise.  Salmonid GH was generously provided by Prof. Akiyoshi Takahashi 
and Dr. Shunsuke Moriyama (Kitasato University, Japan).   
Experimental animals and conditions   
Juvenile rainbow trout of both sexes (ca. 1 year of age) were obtained from Dakota Trout 
Ranch (Carrington, ND).  The animals were transported to North Dakota State University, where 
 92 
they were maintained in well-aerated, 800-L circular tanks supplied with recirculated (10% 
make-up volume per day) dechlorinated municipal water at 14°C under a 12:12 hour light:dark 
photoperiod.  Fish were fed twice daily to satiety with AquaMax Grower (PMI Nutrition 
International, Brentwood, MO, USA) semi-floating trout grower, until commencing experiments 
where fish were fasted continuously for 4 weeks or fed for 4 weeks until 2 hours before 
experimental manipulations. Animals were acclimated to laboratory conditions for at least 4 
weeks prior to experimentation. All procedures were performed in accordance with the Guide for 
Care and Use of Laboratory Animals (National Research Council, Washington, DC) and were 
approved by the North Dakota State University Institutional Animal Care and Use Committee. 
Hepatocyte isolation and serum collection 
At the time of sampling, fish were anaesthetized in 0.05% (v/v) 2-phenoxyethanol, 
measured (body weight and fork length) and euthanized by transection of the spinal cord. In 
some fish, whole blood was collected by caudal venipuncture (Galt et al., 2014), incubated at 
4°C for 1 hour to allow clotting, then centrifuged (11,000 g, 3 min) to secure only the serum and 
stored at -80° C for later analysis. In other fish, hepatocytes were isolated by in situ perfusion 
(Mommsen et al., 1994). The isolated cells were incubated in recovery medium [in mM: 137.8 
NaCl, 5.4 KCl, 0.80 MgSO4, 0.4 KH2PO4, 0.34 Na2HPO4, 4.2 NaHCO3, and 10 HEPES, 0.65 
glucose, pH 7.6, with 2% defatted BSA, 2 ml MEM amino acid mix (50X)/100 ml, and 1 ml 
nonessential amino acid mix (100X)/100 ml] for 2 h at 14°C with gyratory shaking (100 rpm 
under 100% O2. The viability of the cells was assessed by trypan blue dye exclusion and ranged 
between 93-97% for all experiments. After the recovery period, hepatocytes were collected by 
centrifugation (550 g for 8-10 min) and resuspended in incubation media (recovery media with 
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1.5 mM CaCl2) to a final concentration of 2.3 x10
6
 cells/ml and aliquoted into 24-well plates (2.3 
x10
6
 cells/well).  
Previous nutritional state experiment 
Previous nutritional state experiments were designed and executed with (Bergan et al., 
2015). In this experiment, cells were incubated in medium alone (control) or in medium with GH 
as specified in the figure legends under the same conditions as those used for recovery (14°C 
with gyratory shaking at 100 rpm under 100% O2). In combination experiments involving 
pathway inhibition, inhibitors were added 2 h prior to GH treatment at concentrations 
specifically recommended by the manufacturer and/or used by us previously (Reindl et al., 2011) 
as follows: 20 μM LY294002, 10 μM U0126, 50 μM Hex, 10 μM chelerythrine chloride, and 10 
μM U73122 .  After incubation, cells were pelleted (1,000 x g for 4 min) and the supernatant 
medium was removed.  Cells were washed with 0.5 ml phosphate-buffered saline. Samples were 
immediately frozen on dry ice then stored at -80°C until further analysis. 
Cross nutritional state experiment 
Cross nutritional state experiments were designed and executed with (Bergan-Roller et 
al., 2017).For this experiment, cells were incubated in serum from fed or fasted fish with or 
without GH under the same conditions as those used for recovery (14°C with gyratory shaking at 
100 rpm under 100% O2). Concentrations of 10% serum and 100 ng/ml of GH were used. Serum 
treatments lasted for 6 h for mRNA expression with or without GH. After incubation, cells were 
pelleted (1,000 x g for 4 min) and the supernatant medium was removed. Cells were washed with 
0.5 ml phosphate-buffered saline. Samples were immediately frozen on dry ice then stored at -
80°C until further analysis. 
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Somatostatin experiments 
In this experiment, cells were incubated in medium alone (control) or in medium with SS 
as specified in the figure legends under the same conditions as those used for recovery (14°C 
with gyratory shaking at 100 rpm under 100% O2).  In experiments involving pathway 
inhibition, inhibitors were added 2 h prior to GH and/or SS (100 ng/ml of GH and SS) treatment 
at concentrations specifically recommended by the manufacturer and used by us previously 
(Very et al., 2008). After incubation, cells were pelleted (1,000 x g for 4 min) and the 
supernatant medium was removed.  Cells were washed with 0.5 ml phosphate-buffered saline.  
Samples were immediately frozen on dry ice then stored at -80°C until further analysis. 
RNA extraction and analysis 
Total RNA was extracted using TRI-Reagent® (Molecular Research Center, Inc., 
Cincinnati, OH, USA) as specified by the manufacturer’s protocol. Each RNA pellet was 
redissolved in 35–200 μl RNase-free deionized water and quantified by NanoDrop1000 
spectrophotometry (A260) (Thermo Scientific, West Palm Beach, FL, USA). RNA samples were 
then stored at −80 °C until further analysis. 
mRNA was reverse transcribed in 5 μl reactions using 150 ng total RNA and 
AffinityScript QPCR cDNA Synthesis kit reagents (Master Mix, random primers, oligo-dT 
primers, and reverse transcriptase with block) according to the manufacturer’s protocol 
(Stratagene, La Jolla, CA, USA). Reactions without reverse transcriptase were included as 
negative controls to exclude the possibility of contamination with genomic DNA; no 
amplification was detected in negative controls. 
Levels of IGF1 and IGF2 mRNAs were determined by quantitative real-time PCR as 
described previously (Malkuch et al., 2008). Levels of GHR1, GHR2a, and GHR2b were also 
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determined by quantitative real-time PCR as described by Very et al. (2005) and Walock et al. 
(2014). Briefly, real-time reactions were carried out for samples, standards, and no-template 
controls in multiplex reactions with the gene of interest and β-actin. cDNA standards were 
generated using  gene-specific primers; the PCR products were cloned into the pGEM-T Easy 
Vector, and the sequences were verified. Cross reaction was assessed by substituting alternate 
primer/probe sets in assays for each standard; no amplification was observed under these 
conditions. Sample copy number was calculated from the threshold cycle number (CT) and 
relating CT to a gene-specific standard curve, followed by normalization to β-actin. 
Data analysis 
Statistical differences were estimated by one-way or two-way ANOVA, as appropriate.  
In all cases, main effects were significant, and no significant interactions were observed between 
main effects in two-way ANOVAs. In groups with non-normal distribution, data were log 
transformed to attain normal distribution.  Pairwise comparison of simple effects was assessed by 
Duncan’s multiple range test or by Tukey’s range test; statistical notations on the faces of the 
figures reflect such comparisons. A probability level of 0.05 was used to indicate significance. 
Statistics were performed using SigmaStat v. 1.0 (SPSS, Chicago, IL, USA) or JMP v.11 (SAS 
institute Cary, NC, USA) and graphs were constructed with SigmaPlot version 8.0 (SPSS).  
Quantitative data are expressed as means ± SEM.  
Results 
The effect of previous nutritional state on GH-stimulated IGF-1 and IGF-2 expression 
The roles of nutritional state on GH-stimulated IGF expression were examined in vitro 
using isolated hepatocytes from fish either fed continuously or fasted prior to experimentation. 
GH stimulated the expression of IGF-1 and IGF-2 in fed fish in a time- and concentration-
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dependent manner (Fig. 14). Maximal stimulation occurred 6 h treatment for both IGF-1 and 
IGF-2. After 6 h, expression levels decreased continuously though the full 24 h. In concentration 
studies, higher concentrations of GH shower greater ability to stimulate IGF expression with 
maximal expression occurring at 100ng/mL GH and staying high at 1000ng/mL. GH was more 
efficacious in stimulating IGF-2 than IGF-1 showing expression levels higher relative to 
controls. GH was unable to stimulate IGF-1 and IGF-2 expression in hepatocytes from fasted 
fish. 
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Fig. 14. Growth hormone (GH)-stimulated expression of insulin-like growth factor (IGF) 1 and 
IGF-2 mRNAs in hepatocytes isolated from rainbow trout fed continuously or fasted for 4 
weeks.  A: time dependent IGF-1 and IGF-2 mRNA expression in cells incubated for varying 
times with 100 ng/ml GH. B: dose dependent IGF-1 and IGF-2 mRNA expression in cells 
incubated for 6 hours in varying concentrations of GH.  Data are presented as % control and 
expressed as means ± SEM (n=6). Letters denote significant (P<0.05) differences for a given IGF 
subtype across treatments; * denotes a difference in IGF subtypes within a given treatment.; + 
indicates significant difference between cells from different nutritional states for a given IGF 
isoform treated with GH for a given time or at a given concentration. 
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The effect of previous nutritional state on the linkage of cell signaling elements to GH-
stimulated IGF-1 and IGF-2 expression 
The linkage of specific cell signaling pathways to GH-stimulated IGF-1 and IGF-2 
expression in isolated hepatocytes from fish both previously fasted and fed was studied using 
pharmacological inhibitors previously shown effective in rainbow trout. As observed previously, 
GH (100 ng/ml) stimulated IGF-1 and IGF-2 expression in fed cells with GH being more 
efficacious in stimulating IGF-2 expression (Fig. 15). GH was unable to stimulate IGF 
expression in fasted cells. Pretreatment of hepatocytes with the JAK2 inhibitor, hex, completely 
abolished GH-stimulated IGF expression in fed cells. The MEK inhibitor, U0126, and the PI3K 
inhibitor, LY294002, both partially blocked GH-stimulated IGF expression in fed cells. 
However, the PKC inhibitor, chelerythrine chloride, and the PLC inhibitor, U73122, had no 
effect on GH-stimulated IGF expression in fed cells. Signaling pathway inhibitors had no effect 
on GH-stimulated IGF mRNA expression in fasted fish. 
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Fig. 15. The effects of signaling element inhibition on growth hormone (GH)-stimulated 
expression of insulin-like growth factor (IGF) 1 and IGF-2 mRNAs in hepatocytes isolated from 
rainbow trout fed continuously (A) or fasted for 4 weeks (B).  Cells were pretreated for 2 h with 
or without specific inhibitors for the following signaling elements: MEK (10 μM U0126), PI3K 
(10 μM LY294002), JAK (10 μM Hex.), PKC (10 μM chelerythrine chloride), PLC (10 μM 
U73122); after which time, cells were treated with 100 ng/ml GH for 6 h.  Data are presented as 
% control and expressed as means ± SEM (n=6). For a given IGF isoform, groups with different 
letters are significantly (p < 0.05) different.  Letters denote significant (P<0.05) differences for a 
given IGF subtype across treatments. * denotes a difference in IGF subtypes within a given 
treatment. 
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The role of blood serum in reprograming nutritionally regulated GH-stimulated IGF-1 and 
IGF-2 expression 
In an attempt to reprogram cells, and specifically their response to GH, we took 
hepatocytes from each nutritional state (e.g., fed) and treated them with serum from their 
opposite nutritional state (e.g., fasted) as well as with serum from their native nutritional state. 
First we isolated hepatocytes from fish fasted four weeks, and pretreated them with serum 
isolated from other fish fasted 4 weeks or continuously fed. In fasted cells, pretreatment with 
serum from fasted cells had no effect on either IGF-1 or IGF-2 expression (Fig. 16). GH was also 
unable to stimulate either IGF-1 or IGF-2 expression in these same cells as expected. In fasted 
cells, pretreatment with serum from fed cells caused a slight but non-significant increase in IGF-
1 expression but no effect on IGF-2 expression. Thus, pretreating fasted cells with fed serum 
suggested that these cells were reprogrammed to behave like fed cells showing a significant 
increase in GH-stimulated IGF-1 and IGF-2 expression. 
Isolated hepatocytes were also obtained from continuously fed fish and were pretreated 
with serum from other fish fasted for 4 weeks or from continuously fed fish. In fed cells, 
pretreatment with fed serum showed a slight but non-significant decrease in IGF-1 expression 
(Fig. 16). These results were similar to those observed in fed cells treated with fasted serum, 
showing a similar non-significant decrease in IGF-1 expression. Treating these cells with GH 
caused a further slight but non-significant decrease in IGF-1 expression. This decrease was 
significantly different from no-serum controls.  
Serum pretreatment had different results on IGF-2 expression. In fed cells, pretreatment 
with serum from fed cells had no effect on IGF-2 expression. In fed cells pretreated with fed 
serum, GH was able to slightly but non-significantly increase IGF-2 expression. The combined 
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effect of fed serum and GH caused significant increase in IGF-2 expression compared to no-
serum controls. Pretreatment of fed cells with fasted serum caused a slight but non-significant 
increase in IGF-2 expression. In fed cells pretreated with fasted serum, GH surprisingly 
decreased IGF-2 expression back to levels seen in fed cells with no serum. 
 
Fig. 16. The effects of serum on growth hormone (GH)-stimulated expression of insulin-like 
growth factor (IGF) 1 (A and B) and IGF-2 (C and D) mRNAs in hepatocytes isolated from 
rainbow trout fed continuously (A and C) or fasted for 4 weeks (B and D). Cells were treated for 
24 hours with 10% serum harvested from the blood plasma of fed or fasted fish then treated with 
or without 100 ng/ml of GH for 6 hours. Data are presented as log10 copies and expressed as 
means ± SEM (n=6). Letters denote significant (p < 0.05) difference within a nutritional state 
and IGF subtype. 
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The effect of somatostatin on IGF-2 expression 
The role of SS on IGF-2 expression was examined in vitro using isolated hepatocytes 
from rainbow trout.  SS (100 ng/ml) was shown to inhibit IGF-2 expression in a time dependent 
manner (Fig. 17). Slight but non-significant inhibition was first observed at 6 h. Maximal 
inhibition of IGF-2 expression was observed at 12 h and the inhibition started to decrease at 24 h. 
SS inhibition of IGF-2 expression was not found to be significant in a concentration response 
study. 
The linkage of cell signaling elements to SS inhibition of GH-stimulated IGF-2 expression 
The linkage of specific cell signaling pathways to the SS inhibition of GH-stimulated 
IGF-2 expression in isolated hepatocytes was studied using pharmacological inhibitors. GH was 
first shown to slightly but non significantly increase IGF-2 expression. In this study, the AKT 
inhibitor, carb, was shown to decrease GH-stimulated IGF-2 expression in combination with SS 
more than SS on its own. The MEK inhibitor, U0126, with GH was shown to have a combined 
inhibition slightly but not significantly greater than just SS alone but significantly decreased 
from GH treated cells (Fig. 17). AKT inhibition was shown to have a greater effect on GH-
stimulated IGF-2 expression than MEK inhibition. 
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Fig. 17. The effects of somatostatin (SS) on insulin like growth factor (IGF) 2 expression and the 
role of SS and signaling element inhibition on growth hormone stimulated IGF-2 mRNA 
expression in hepatocytes isolated from rainbow trout. A: time dependent IGF-2 mRNA 
expression in cells incubated for varying times with 100 ng/ml SS. B: dose dependent IGF-2 
mRNA expression in cells incubated for 6 hours in varying concentrations of SS. C: Hepatocytes 
were preincubated for 2 h with specific inhibitors for the following signaling elements: MEK (10 
μM U0126=MEK-I) and Akt (10 μM Carb=Akt-I.) Cells were treated with combinations of 100 
ng/ml GH and or SS for 6 h. Data are presented as log10 copies and expressed as means ± SEM 
(n=10). Letters denote significant (p < 0.05) differences between treatments.  
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The effect of previous nutritional state on GH-stimulated GHR1, GHR2a, and GHR2b 
expression 
The role of nutritional state on GH-stimulated GHR expression was examined in vitro 
using isolated hepatocytes from fish either fed continuously or fasted prior to experimentation 
(Fig. 18 and 19). GH treatment was shown to have a positive effect on GHR1 expression in both 
fed and fasted fish. GH treatment at doses 10ng/ml and 1000ng/ml caused a significant and equal 
increase in GHR1 expression in fed fish, while 100ng/ml showed slight but non-significant 
increase (Fig. 18).  Fasted fish only saw a slight but non-significant increase in GHR1 expression 
at the 100 ng/ml GH dose. However this increase was significantly different from 1ng/ml 
treatments. GH treatment at differing doses was shown to have no effect on either GHR2a or 
GHR2b in either fed or fasted fish.    
The relationship with time based treatments of GH had a more complicated relationship 
with GHR expression. GH was shown to cause a decrease in GHR1 in a time dependent manner 
in both fed and fasted fish. In both fed and fasted fish this decrease is seen at 12 and 24 hours.  
As previously observed, GH treatments had no effect on GHR2a in either fed or fasted fish. 
However, GH treatment caused a slight but non-significant decrease in GHR2b expression 
occurring at 12 h and continuing through 24 h in fed fish while fasted fish first saw a slight but 
non-significant decrease at 12 h and significant decrease at 24 h (Fig. 19).  
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Fig. 18. Growth hormone (GH)-stimulated expression of growth hormone receptor (GHR) 1, 
GHR2a, and GHR2b mRNAs in hepatocytes isolated from rainbow trout fed continuously. A, C, 
and E: time dependent GHR1 (A and B), GHR2a, (C and D) and GHR2b (E and F) mRNA 
expression in cells incubated for varying times with 100 ng/ml GH. B, D, and F: dose dependent 
GHR1, GHR2a, and GHR2b mRNA expression in cells incubated for 6 hours in varying 
concentrations of GH. Data are presented as log10 copies and expressed as means ± SEM (n=6). 
Letters denote significant (p < 0.05) difference within a given treatment and GHR subtype. 
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Fig. 19. Growth hormone (GH)-stimulated expression of growth hormone receptor (GHR) 1, 
GHR2a, and GHR2b mRNAs in hepatocytes isolated from rainbow trout fasted for 4 weeks. A, 
C, and E: time dependent GHR1 (A and B), GHR2a, (C and D) and GHR2b (E and F) mRNA 
expression in cells incubated for varying times with 100 ng/ml GH. B, D, and F: dose dependent 
GHR1, GHR2a, and GHR2b mRNA expression in cells incubated for 6 hours in varying 
concentrations of GH. Data are presented as log10 copies and expressed as means ± SEM (n=6). 
Letters denote significant (p < 0.05) difference within a given treatment and GHR subtype. 
 
The effect of previous nutritional state on the linkage of cell signaling elements to GH-
stimulated GHR1, GHR2a, and GHR2b expression 
The linkage of specific cell signaling pathways to GH-stimulated GHR1, GHR2a, and 
GHR2b expression in isolated hepatocytes from fish both previously fasted and fed was studied 
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using pharmacological inhibitors previously shown effective in rainbow trout. GH was shown to 
have no effect on GHR1 expression in fed fish unlike our earlier observations. As seen before, 
GH treatment had no effect on GHR2a or GHR2b expression. JAK inhibition caused a 
significant decrease in GH-stimulated GHR1 expression in fed fish, this difference was 
significant compared to all groups and other inhibitors. Signaling pathway inhibitors had a very 
complicated relationship with GH-stimulated GHR2a expression. While no inhibitor alone 
caused a significant change from GH controls, PLC inhibition both caused a slight but non-
significant decrease in GH-stimulated GHR2a expression.  In fed fish, MEK inhibition caused a 
significant increase in GH-stimulated GHR2a expression compared to PLC inhibition.  In fed 
fish, all pharmacological inhibitors had no effect on the GH-stimulated expression of GHR2b 
(Fig. 20).  
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Fig. 20. The effects of signaling element inhibition on growth hormone (GH)-stimulated 
expression of growth hormone receptor (GHR) 1 (A and B), GHR2a, (C and D) and GHR2b (E 
and F) mRNAs in hepatocytes isolated from rainbow trout fed continuously (A, C, and E) or 
fasted for 4 weeks (B, D, and F).  Cells were pretreated for 2 h with or without specific inhibitors 
for the following signaling elements: MEK (10 μM U0126), PI3K (10 μM LY294002), JAK (10 
μM Hex.), PKC (10 μM chelerythrine chloride), PLC (10 μM U73122); after which time, cells 
were treated with 100 ng/ml GH for 6 h. Data are presented as log10 copies and expressed as 
means ± SEM (n=6). Letters denote significant (p < 0.05) difference within a nutritional state 
and GHR subtype. 
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Fasted fish were shown to have a complicated relationship with pharmacological 
inhibitors and their effects on GHR expression. GH was also shown to cause a slight but non-
significant decrease in GHR1expression similar to what we observed in time studies but opposite 
of what we saw in dose studies. GH was shown to have no effect on GHR2a in fasted fish (Fig. 
20). GH was also shown to cause a slight but non-significant decrease in GHR2b expression. In 
fasted fish, PLC inhibition was shown to cause a significant decrease in GH-stimulated GHR2a 
expression when compared to all groups expect GH treatment similar to what was seen in fed 
fish. JAK, PI3K, and PKC inhibition all caused a slight but non-significant increase in GH-
stimulated GHR2a expression, while MEK inhibition had no effect on GH-stimulated GHR2a 
expression. These pharmacological inhibitors had a similar effect on GH-stimulated GHR2b 
expression compared to GH-stimulated GHR2a expression. While not significantly different 
from GH controls, PLC inhibition caused a significant decrease in GH-stimulated GHR2b 
expression compared to PKC, PI3K, and JAK inhibition. Just like with GH-stimulated GHR2a 
expression, JAK and PI3K inhibition all caused a slight but non-significant increase in GH-
stimulated GHR2b expression, while PKC caused a significant increase in GH-stimulated 
GHR2b expression compared to GH controls. MEK had no effect on GH-stimulated GHR2b 
expression. GH-stimulated GHR1 expression was also similarly effected by pharmacological 
inhibitors in fasted fish. PKC and PI3K inhibition, along with GH, counteracted the decrease in 
GHR1 expression caused by GH alone and brought GHR1 expression levels back towards 
control levels. JAK and MEK had no significant effect on GH-stimulated GHR1 expression 
compared to GH controls. PLC caused significantly lower levels of GH-stimulated GHR1 
expression from all groups except GH and MEK continuing the trend we see when PLC and GH 
cause the lowest levels of GH-stimulated GHR expression. 
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The role of blood serum in reprograming nutritionally regulated GH-stimulated GHR1, 
GHR2a, and GHR2b expression 
In an attempt to reprogram cells, and specifically their response to GH, we took 
hepatocytes from each nutritional state (e.g., fed) and treated them with serum from their 
opposite nutritional state (e.g., fasted) as well as with serum from their native nutritional state.  
In fed fish the serum pre-treatment had very minimal effect on GHR expression (Fig. 21). Pre-
treatment of fed cells with fed and fasted serum caused a slight but non-significant increase in 
GHR1 expression.  In fed cells pre-treated with fed serum GH was able to further increase GHR1 
expression to levels significantly higher than no serum treated cells. In fed cells treated with 
fasted plasma GH slightly but non-significantly decreased GHR1 expression. Pre-treatment with 
either serum had no effect on either GHR2a or GHR2b mRNA expression. In addition, GH had 
no effect on either GHR2a or GHR2b mRNA expression in cells from fed fish with either serum 
treatment.  
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Fig. 21. The effects of serum on growth hormone (GH)-stimulated expression of growth 
hormone receptor (GHR) 1 (A and B), GHR2a, (C and D) and GHR2b (E and F) mRNAs in 
hepatocytes isolated from rainbow trout fed continuously (A, C, and E) or fasted for 4 weeks (B, 
D, and F). Cells were treated for 24 hours with 10% serum harvested from the blood plasma of 
fed or fasted fish then treated with or without 100 ng/ml of GH for 6 hours. Data are presented as 
log10 copies and expressed as means ± SEM (n=6). Letters denote significant (p < 0.05) 
difference within a nutritional state and GHR subtype. 
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In hepatocytes from fasted fish, pre-treatment with either serum from fed fish or fasted 
fish increased GHR1, GHR2a, and GHR2b mRNA expression (Fig. 21). For each GHR, mRNA 
expression was increased to the same level with serum from fasted and fed fish. In fasted cells 
pre-treated with serum from fed fish, the addition treatment with GH caused a slight but non-
significant increase in GHR1, GHR2a, and GHR2b expression. In fasted cells pre-treated with 
serum from fasted cells, the additional treatment of GH caused a slight but non-significant 
decrease in GHR1, GHR2a, and GHR2b. While both the GH-stimulated increase in GHR 
expression in fasted cells treated with fed serum and the GH-stimulated decrease in GHR 
expression in fasted cells treated with fasted serum were not significant, they were significantly 
different from each other in all three GHRs. 
Discussion 
GH-stimulated IGF expression is dependent on nutritional state. GH was only able to 
stimulate IGF-1 and IGF-2 mRNA expression in hepatocytes from fed cells as opposed to 
hepatocytes isolated from fasted fish. This is consistent with other research showing GH 
promoting IGF-1 expression in rainbow trout hepatocytes (Reindl et al., 2011) and IGF-2 
expression in multiple species of fish (Shamblot et al., 1995; Pierce et al., 2010). This helps 
explain the fact that fasting causes a decrease in plasma IGF-1 levels (Gomez-Requeni et al., 
2005; Norbeck et al., 2007). GH-stimulated hormone sensitive lipase (HSL) expression is 
dependent on nutritional state, with GH causing increased HSL expression only in fasted fish but 
not in fed fish (Bergan et al., 2015).  The increase in HSL expression can be assumed to also lead 
to an increase in lipolysis. HSL was chosen as a target to measure lipolysis because HSL and 
adipose triacyglyceride lipase account for 90% of lipolysis  through the hydrolysis of fatty acids  
off the glycerol backbone of the triacylglycerides (Watt and Spriet, 2010; Jaworski et al., 2007). 
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This is consistent in the literature finding GH-stimulated lipolysis in the livers of fish (Bergan et 
al., 2013; O’Connor et al., 1993). These two facts taken together illustrate that GH has multiple 
different roles in the same cells dependent on nutritional state in both growth and lipolysis.  This 
also explains the increase in GH in fasting fish (Gomez-Requeni et al., 2005; Norbeck et al., 
2007; Picha et al., 2008; Reinecke, 2010) despite that fact that GH in not active in increasing IGF 
expression. 
Somatostatin plays a role in the regulation of growth via IGF-2 expression. This 
conclusion was supported through the observation that SS decreased IGF-2 expression in a time 
dependent manner. While not significant in a concentration related manner this is possible since 
the largest effect on IGF-2 was observed at the later time point of 12 h in the dose study was 
conducted at 6 h. This is similar to what was previously seen in the literature with SS causing 
decreased IGF-1 expression in rainbow trout (Very et al., 2008) and similar to the observation of 
SS decreasing IGF-2 expression in orange-spotter grouper (Wang et al., 2016). AKT and MEK 
inhibition was shown to decrease GH-stimulated IGF-2 expression in combination with SS to 
below base levels.  Little can be inferred from this inhibition study,  but it shows that the AKT 
and MEK pathways are active in GH-stimulated IGF-2 expression, as shown by other research 
that GH-stimulated IGF expression works through the AKT and MEK pathways (Reindl et al., 
2011). This study would benefit from being repeated with larger sample sizes and more 
inhibitors to increase statistical power and more fully elucidate the pathways these processes 
work through. These observations together help to further establish the role of IGF-2 in post 
embryonic growth in teleost. 
GH-stimulated GHR expression is not dependent on nutritional state. This conclusion is 
supported by the observations that the nutritional state of the fish caused no change in how the 
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hepatocytes reacted to GH relative to GHR1, GHR2a, or GHR2b mRNA expression. While the 
role of GH has been well studied on GHR expression, the results are conflicting. In rainbow trout 
GH treatment was shown to increase GHR expression (Very and Sheridan 2007), while in black 
seabream GH was shown to have no effect on GHR expression (Jiao et al., 2006) and rats have 
shown that GH treatment decreases GHR expression (Maiter et al., 1988).  Our observation that 
GH caused an increase in GHR1 expression in both fed and fasted fish is similar to the effects 
observed in rainbow trout while our observation that GH had no effect on GHR2a or GHR2b 
expression is more similar to the results seen in black seabream.  
In time-course studies we saw different results that in the longest GH treatment of 12 and 
24 h GH caused a decrease in all GHRs. This suggests a feedback mechanism of long term GH 
treatment causing decreased GHR receptors for the GH to work upon in longer treatments.   
Despite the fact that we found nutritional state to have no effect on how cells react to GH, 
the role of nutritional state on GHRs in the liver has been well studied. Fasting has previously 
been shown to decrease GHR expression in the hepatocytes of many fish including rainbow trout 
(Norbeck et al., 2007), masu salmon (Fukada et al., 2004), black seabream (Deng et al., 2004), 
cat fish (Small et al., 2006), and striped sea bass (Picha et al., 2008) while fasting was shown to 
have no effect on GHR expression in tilapia (Pierce et al., 2007). This information taken together 
suggests that while both nutritional state and GH are important in regulating GHR, nutritional 
state is not important in how cells react to GH in regards to GHR expression. 
JAK/STAT and PI3K/Akt are the pathways through which nutritionally dependent GH-
stimulated IGF expression occurs. This conclusion is backed by several observations.  JAK2 
inhibition completely abolished GH-stimulated IGF expression in fed cells, and MEK and PI3K 
inhibition both partially blocked GH-stimulated IGF expression in fed cells. This is similar to 
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what we observed in our earlier studies as wells as the literature showing that GH works though 
the JAK/STAT and PI3K/Akt pathways (Reindl et al., 2011). The second observation that 
protein kinase C (PKC) and phospholipase c (PLC) inhibition had no effect on GH-stimulated 
IGF expression in fed cells also supported this initial conclusion as these two inhibitors are used 
to inhibit lipolysis and had no effect on IGF expression. The fact that PKC and PLC inhibition 
completely block GH-stimulated lipolysis and GH-stimulated HSL expression while JAK/STAT 
and PI3K/Akt inhibition had no effect (Bergan et al., 2013), further establishes our conclusion 
that nutritional state switches the cells responsiveness to GH. This information also illustrates 
that different responses to GH growth vs lipolysis are controlled by different signaling pathways.  
As observed previously, the relationship between nutritional state and GH-stimulated 
GHR expression is very complicated. Since GH stimulation in general has a small effect on GHR 
expression, it was difficult to find many patterns in the data regarding nutritional state and 
pathway inhibition. Inhibiting signal pathways in general had a much lesser effect in fed fish 
compared to fasted fish, with the only significant effect being the difference between slight 
negative effects of PLC inhibition compared to the slight increase in GH-stimulated GHR2a 
expression caused by MEK inhibition. The only other difference in fed fish was that JAK 
inhibition caused significant decrease in GH-stimulated GHR1 expression compared to every 
other treatment. This is similar to our observation that in fed fish the inhibition of JAK led to the 
complete blockage of GH-stimulated IGF expression. This observation is consistent with the 
literature that JAK activation is the first step in GH action as observed in both fish (Reindl et al., 
2011) and in mammals (Waters et al., 2006; Piwien-Pilipuk et al., 2002). This suggests that JAK 
activation is important in regulating its own future actions by inhibiting GHR1 expression in fed 
fish. 
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The relationship between inhibitors and GH-stimulated GHR expression in fasted fish 
was even more complicated. Compared to fed fish, more inhibitors had an effect on GH-
stimulated GHR expression. In fasted fish, several general trends were observed. The first being 
that PLC inhibition caused a decrease in GH-stimulated GHR expression for every GHR. A 
similar effect was only noticed on GHR2a expression in fed fish. This inhibition was also more 
pronounced in fasted fish. Another trend found is that PKC inhibition caused a slight increase in 
GH-stimulated GHR expression with every GHR. This was different from what was seen in fed 
fish, as in every group PKC inhibition as found to have no effect. Other research has similarly 
shown that both PKC and PLC inhibition completely abolished GH-stimulated HSL expression 
and lipolysis, observed as glycerol release, that was only present in fasted fish (Bergan et al., 
2015). Although no clear effect of GH-stimulated GHR expression was observed in the present 
study, our results support the proposed mechanism that nutritional state is changing how cells 
react to GH. In a fed state, cells respond to GH through the JAK/STAT and PI3K/Akt pathways 
while in fasted fish GH works through PLC and PKC pathways. 
The ability of cells to respond differentially to GH in different nutritional states is 
regulated by serum. Fasted cells that are pre-treated with serum from fed cells react like fed cells 
when treated with GH. Normally in fasted cells, GH treatment has no effect on IGF-1 or IGF-2 
expression, but when treated with serum from fed fish GH treatment caused an increase in both 
IGF-1 and IGF-2 expression as seen in fed fish. This is also similar to results seen in the 
literature for GH-stimulated IGF-1 (Reindl et al., 2011) and IGF-2 expression in multiple species 
of fish (Shamblot et al., 1995; Pierce et al., 2010).  Similar reprograming was also observed in 
fed cells. In fed cells pretreatment of cells with fasted serum caused GH to cause significant 
decreases in both IGF-1 and IGF-2 expression compared to no serum controls. This is similar to 
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the previous observation that GH has no effect on IGF expression in fasted cells, but this goes 
one step further showing the levels of IGF-1 and IGF-2 decreasing from the higher levels they 
would have be at in times of feeding (Gomez-Requeni et al., 2005; Norbeck et al., 2007). This 
suggests that the serum is again changing how the cells react to GH.  These observations along 
with the fact that a similar effect was also observed by us that serum was able to reprogram fed 
cells to react like fasted cells when treated with GH in regards to HSL expression and lipolysis 
(Bergan-Roller et at., 2017) form a strong hypothesis that serum contains one or more factors 
that allow cells to differentially react to GH in different nutritional states.  
Serum was also found to have a role in IGF-1 and IGF-2 expression.  In fasted cells 
treatment with fed serum caused a slight but not significant increase in IGF-1 expression. This is 
probably from other elements already in the serum such as GH that would naturally cause an 
increase in IGF-1 as seen in literature (Reindl et al., 2011). Interestingly in fed cells treatment 
with fasted serum caused a slight but not significant decrease in both IGF-1 and IGF-2 
expression. This is similar to what is seen in fasting organisms having decreased levels of IGF-1 
(Gomez-Requeni et al., 2005; Norbeck et al., 2007) suggesting that the fasted serum is causing 
the fed cells to react as if they were fasted. Further studies should be done on individual 
components of the serum such as insulin, IGF, and perhaps others to see what roles they play on 
the reprograming of cells in response to GH in regards to IGF and GHR expression similar to 
what was done in (Bergan-Roller et al., 2017) in regards to lipolysis and HSL expression.  
Serum plays a role in regulating GHR expression in fasted fish. This conclusion is 
supported by several observations. First in fasted cells treatment with either serum caused an 
increase in GHR1, GHR2a, and GHR2b expression. This suggests that something in the serum is 
causing an increase in GHR expression. As mentioned earlier, this would be a good avenue for 
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further studies to find which components in the serum cause this increase. The serum also 
reprogramed how the cells would respond to GH. In fasted cells, after pretreatment with fed 
serum, GH caused an additional increase in GHR1, GHR2a, and GHR2b, expression levels, but 
in similar cells treatment with fasted serum caused the cell to react to GH by causing decreased 
levels of GHR1, GHR2a, and GHR2b expression. Although we observed that nutritional state 
didn’t cause any changes in cells response to GH in regards to GHR expression, some 
component in the serum that changed in response to the change in nutritional state did cause the 
cells to react differently to GH. This is another area for future research. These effects of serum 
on GHR expression and reprograming cells in regards to response to GH are only observed in 
fasted fish, whereas in fed fish, serum has very little effect on either GHR expression or GH-
stimulated GHR expression. This suggests that the fasted cells are more sensitive to the serum as 
a result of food depravation.  
In summary we found that nutritional state modulates the growth-promoting actions of 
GH but not the expression of GHRs. The growth promoting action of GH that we studied in this 
experiment was the expression of IGF encoding mRNAs. During feeding, GH activates the JAK-
STAT, PI3K/Akt, ERK pathways resulting in the increased expression of IGFs. During periods 
of fasting, on the other hand, GH activates a different complement of signal pathways 
(PLC/PKC) that do not promote growth. This suggests that some mechanism is switching how 
these cells react under the different nutritional states. We proposed that serum was the mediator 
of this change in regards to IGF expression. When treated with serum from the opposite 
nutritional state cells would act according to the nutritional state of the serum they were treated 
with as opposed to their native nutritional state. The expression of GHRs was not as clearly 
regulated by nutritional state or serum. While nutritional state didn’t cause a direct change in 
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how cells reacted to GH in regards to GHR expression, serum treatment did change how cells 
react to GH. These findings help provide insight into the diverse actions of GH in different 
nutritional states. We suggest that individual elements in the serum are responsible for this 
switching of cell responsiveness.  Further studies should be conducted to determine what 
elements of the serum are active in causing this switch. In addition, further studies could be done 
on the different GHRs to determine which GHRs are selectively active during different 
nutritional states to see if this is helping to promote the switch between the growth promoting 
and lipolytic actions of GH. 
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CHAPTER 5: GENERAL CONCLUSIONS 
Growth hormone family peptides such as GH, PRL, and SL regulate a wide array of 
physiological actions including but not limited to growth, feeding, metabolism, reproduction, 
osmoregulation, immune function, behavior, stress, chromatophore regulation, pigmentation, and 
lipolysis. This wide array of actions is regulated on many different levels and by a multitude of 
factors both internal and external. Even though the most studied action of GH is growth 
promotion, it is not fully understood. Through this research, my goal was to contribute to the 
understanding of the actions of GH family peptides and determine more of the underlining 
mechanisms through which GH conducts its diverse actions in times of differing nutritional 
availability in rainbow trout (Oncorhynchus mykiss). This was done by characterizing a novel 
GHR and determining how nutritional state regulates its expression. Next, the effects of GH 
family peptides on the growth promoting actions of GH as observed by IGF-1 and IGF-2 
expression and which signaling pathways these actions utilize were demonstrated. Finally, the 
ability of nutritional state to change the actions of GH in vitro and the role of serum as a 
mediator of this change in cells sensitivity to GH was studied. 
A new GHR was discovered and characterized in rainbow trout. The discovery of this 
new GHR helps clarify the evolution and naming of vertebrate GHRs. Phylogenetic analysis 
identified this GHR as a type 1 GHR, and suggested using the naming change suggested by 
Ellens et al., (2013). GHR1 mRNA was differently expressed among all tissues examined, with 
the highest levels observed in liver and white muscle. This is consistent with the multitude of 
diverse actions in GH in many different tissues. The expression levels of this new GHR were 
found to be much lower than with other trout GHRs (cf. Very et al., 2005). This new GHR 
shared many conserved features among other GHRs. In the extracellular domain this consisted of 
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hormone binding regions, a Y/FGEFS motif, cysteine residues, and potential N-glycosylation 
sites. This receptor also contained a single transmembrane domain as with all GHRs. 
Additionally the intercellular domain contains conserved phosphorylation sites used in linking to 
cell signaling pathways. 
The expression of GHR1 is changed by nutritional state. Short term fasting (2 week) was 
shown to decrease GHR1 mRNA expression in both adipose and red muscle. Similar decreases 
were observed in liver after long term fasting (4 weeks). Feeding brought decreased GHR1 
expression back up to levels seen in fed fish in both liver and adipose tissue. Similar effects were 
observed after re-feeding in white muscle, but not statistically significant. Fasting decreased 
GHR expression was similar to results seen in other species of fish (Deng et al., 2004; Picha et 
al., 2008;Fukada et al., 2004; Small et al., 2006; Norbeck et al., 2007; Peterson et al., 2009). 
Some differential expression of different GHRs in regards to fasting is also present. GH has been 
shown to increase GHR2a expression in adipose tissue (Norbeck et al., 2007) as well as increase 
GHR2 expression in muscle of striped bass and tilapia (Picha et al., 2008; Fox et al., 2010). This 
differential regulation of GHRs is a possible mechanism for reduced growth promoting aspects 
of GH in times of fasting while other actions that are needed in fasting, e.g., lipolysis, flourish. 
Somatotropin family hormones stimulate growth through IGF-1 and IGF-2. GH 
implantation caused increased growth in rainbow trout via increased food conversion as observed 
in both increases in length and mass. In vivo GH increased both IGF-1 and IGF-2 mRNA 
expression. Similar results were also observed in vitro as GH was shown to increase both IGF-1 
and IGF-2 expression in a time and dose dependent manner in hepatocytes. PRL also increased 
both IGF-1 and IGF-2 expression in a time and dose dependent manner in vitro. SL did not cause 
any change in either IGF-1 or IGF-2 expression. Our results are similar to other research 
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revealing that GH has been shown to increase IGF-1 expression in rainbow trout hepatocytes 
(Reindl et al., 2011), as well as IGF-2 expression in other fish (Shamblot et al., 1995; Pierce et 
al., 2010). Previous research has also show the ability of PRL to increase IGF-1 levels in rats 
(Hill et al., 1977) and IGF-2 levels in bats (Viengchareun et al., 2008). The fact that SL was 
unable to stimulate IGF illustrates that SL in less involved in growth regulation. 
GH- and PRL-stimulated IGF-1 and IGF-2 expression is mediated through common 
signaling pathways including ERK, PI3K/Akt, and JAK-STAT. The first demonstrated pathway 
for GH and PRL actions was ERK. GH and PRL directly induce the phosphorylation of ERK1/2. 
Also, blocking the ERK pathway with a MEK inhibitor partially inhibited GH- and PRL-
stimulated IGF expression. Next, GH and PRL were shown to act through the PI3K/Akt 
pathway. GH and PRL directly induced the phosphorylation of Akt. This conclusion was further 
strengthened through both PI3K and Akt inhibition causing the inhibition of GH- and PRL-
stimulated IGF expression. Finally, GH and PRL were found to work through the JAK-STAT 
pathway. GH and PRL directly induced the phosphorylation of JAK2 and STAT5. Furthermore, 
JAK2 inhibition completely inhibited GH- and PRL-stimulated IGF expression. However, 
STAT5 inhibition partially blocked GH- and PRL-stimulated IGF expression. The pathways we 
found GH to work through are the same as those found in the literature to be activated by GH 
and during IGF-1 expression (Argetsinger and Carter-Su 1996; Kopchick and Andry 2000; 
Piwien-Pilipuk et al., 2002). PRL has also been shown to activate the pathways of ERK (Gubbay 
et al., 2002), PI3K/Akt (Richert et al., 2001), and JAK2-STAT5 (Campbell et al., 1994; Pezet et 
al., 1997). Taken together this information helps further clarify the GH and PRL signaling 
transduction as well as illustrating possible mechanisms that GH can utilize to conduct its many 
diverse actions. 
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SS regulates growth through IGF-2 expression. This is supported by our observation that 
SS caused decreased IGF-2 expression. The role of SS is well studied in regards to IGF-1 but 
regulation through IGF-2 is less studied. Our observation is similar to others who demonstrated 
the ability of SS to decrease both IGF-1 (Very et al., 2008) and IGF-2 expressions (Wang et al., 
2016).  We also demonstrated that AKT and MEK would decrease GH-stimulated IGF-2 
expression in combination with SS to below basal levels. This helps to further establish the role 
of SS in regulating growth through IGF-2 in addition to IGF-1 and also confirms that GH-
stimulated IGF-2 expression is mediated through pathways similar to those previously observed 
by us and other studies (Reindl et al., 2011). These findings together with the ability of GH and 
PRL to stimulate IGF-2 expression help to further establish the role of IGF-2 in post embryonic 
growth in teleost fish as opposed to its initial proposed role of only promoting embryonic 
growth. 
Nutritional state regulates the actions of GH. GH-stimulated IGF expression is regulated 
by nutritional state. GH-stimulated IGF-1 and IGF-2 mRNA expression was only observed in 
cells from fed fish and not those from fasted fish. This is consistent with literature showing GH 
stimulation of IGF-1 (Reindl et al., 2011) and IGF-2 expression (Shamblot et al., 1995; Pierce et 
al., 2010). The fact that GH did not illicit a response in fasting fish is supported by the 
observation that fasting causes a decrease in plasma IGF-1 levels despite increased GH levels 
(Gomez-Requeni et al., 2005; Norbeck et al., 2007), suggesting the increased GH is working on 
other actions in times of fasting. However, GH-stimulated GHR expression does not depend on 
nutritional state, as the changing nutritional state did not affect how cells react to GH in regards 
to GHR1, GHR2a, or GHR2b mRNA expression. While nutritional state had no role in GH-
stimulated GHR expression, we nonetheless found some effect of GH on GHR expression. GH 
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caused an increase in GHR1 expression but had no effect on GHR2a or GHR2b. The effect of 
long term (12 and 24 hour) treatment with GH was shown to decrease all GHRs suggesting a 
long term feedback mechanism. The effects of GH on GHR expression have been very 
conflicting as GH has been shown to increase GHR expression, (Very and Sheridan 2007), have 
no effect on GHR expression (Jiao et al., 2006), and decreases GHR expression (Maiter et al., 
1988). Our differing results on the effects of GH on GHR expression by GHR subtype mirrors 
the conflicting results illustrated in the literature.   
Nutritional-dependent GH-stimulated IGF expression is mediated through the ERK, 
JAK/STAT, and PI3K/Akt signaling pathways. This is supported by the observations that JAK2 
inhibition completely inhibited GH-stimulated IGF expression, and MEK and PI3K inhibition 
both partially blocked GH-stimulated IGF expression. These are the same pathways we observed 
GH to work through relative to IGF expression as well as having been seen in other studies 
(Reindl et al., 2011). The use of lipase-related inhibitors PKC and PLC had no effect on GH-
stimulated IGF expression in fed cells. Taken together with the fact that PKC and PLC inhibition 
inhibited lipolysis while JAK/STAT and PI3K/AKT inhibition had no effect on lipolysis (Bergan 
et al., 2013), confirms that nutritional state changes the responsiveness to cells to GH and this 
change is mediated via alternative signaling pathways.  
As observed earlier, nutritional state has no effect on GH-stimulated GHR expression and 
GH also had little effect on GHR expression. These facts limit what can be learned through the 
use of cell signaling inhibitors. The only real conclusion in fed fish is that JAK inhibition caused 
a significant decrease in GH-stimulated GHR1 expression compared to every other treatment. 
This is similar to the fact the JAK activation is the first step in GH cell signaling (Waters et al., 
2006; Piwien-Pilipuk et al., 2002).  Additionally in fasted fish, PKC inhibition caused a slight 
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increase in GH-stimulated GHR expression. This is similar to other observations that PKC 
inhibition is active in GH-stimulated HSL expression and lipolysis only in fasted fish (Bergan et 
al., 2015). While nutrition state had no effect on GH-stimulated GHR expression, these 
observations help further the understanding of the multiple signaling pathways utilized by GH in 
different nutritional states. 
The differential response of cells to GH is mediated by serum. This conclusion is 
supported by 2 observations. The pre-treatment of fasted cells with serum from fed cells causes 
those fasted cells to act like fed cells. Just like observed earlier, GH had no effect on IGF 
expression in fasted cells, but after pre-treatment with serum from fed cells, GH treatment caused 
an increase in IGF-1 and IGF-2 expression as similar to what we see in fed fish. Similar 
reprograming was observed in fed cells. Pre-treatment of these fed cells with fasted serum 
caused GH to significantly decrease IGF-1 and IGF-2 expression. This is similar to our 
observation that in fed cells GH had no effect on IGF expression, but this also goes further by 
actively decreasing IGF from their higher levels normally seen in feeding to lower levels as 
observed in fasting (Gomez-Requeni et al., 2005; Norbeck et al., 2007). These two observations 
along with the previous studies from our lab showing similar results of serum making fed cells 
act like fasted cells when treated with GH with HSL expression and lipolysis (Bergan-Roller et 
al., 2017) provide a strong basis for the conclusion that serum is the factor that regulates the 
different actions of GH under different nutritional states. Serum treatment also changed how 
cells react to GH relative to GHR expression. In fasted cells, pre-treatment with fed serum plus 
GH treatment caused an increase in the expression of all GHRs but, pre-treatment with serum 
from fasted cells plus GH caused a decrease in the expression of all GHRs. Despite the fact that 
nutritional state had no effect on GH-stimulated GHR expression, some component in serums 
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from different cells did change how the cells respond to GH. These actions were only limited to 
fasted cells. Fed cells serum treatment had no effect on GH-stimulated GHR expression, 
suggesting that fasted cells are more sensitive to the particular factors in serum due to the lack of 
food. 
Serum treatment also affects both IGF and GHR expression directly. First we observed 
serum to have an effect on IGF expression. In fasted cells, treatment with serum from fed cells 
caused a slight increase in IGF-1 expression. This increase is probably caused by high GH levels 
in fasted fish that would cause an increase in IGF expression (Reindl et al., 2011). Interestingly 
in fed cells, treatment with serum from fasted cells caused a slight decrease in IGF-1 and IGF-2 
expression similar to the observation that fasted organisms naturally have lower level of IGF-1 
(Gomez-Requeni et al., 2005; Norbeck et al., 2007). This suggests that something present in or 
absent from fasted serum is causing these fed cells to act as if they were fasted. The effects of 
serum were also observed on GHR expression. In fasted cells, treatment with any serum caused 
an increase in all the expression of all GHRs suggesting that some common element in both 
serums is causing this increase. No effects were observed with either serum treatment on fed 
cells. As with GH-stimulated GHR expression, this may suggest that fasted cells are more 
sensitive to serum. 
Future studies 
The ability of GH to perform its vast array of actions may be mediated though different 
GHR receptor subtypes. It is known that fish possess multiple GHRs (Perez-Sanchez et al., 2002; 
Walock et al., 2014) including a newly discovered GHR that was first characterized by our 
group. While some work has been done on the different GHR subtypes (Reindl and Sheridan, 
2012), further work needs to be done to fully investigate the roles of the different GHR subtypes. 
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This is even more important with the discovery of our new GHR in rainbow trout, which has not 
yet been studied extensively. This characterization could be achieved by creating cell lines that 
only express one GHR subtype. These individual receptors may play different roles in the 
diverse actions of GH in different nutritional states. For example one GHR may be responsible 
for the growth promoting actions of GH such as IGF production during times of feeding while 
another may be more active in catabolic actions such as lipolysis in times of fasting. We also 
know that the GHRs in rainbow trout are differentially distributed (Walock et al., 2014; Very et 
al., 2005), providing further reason to believe the GHRs have unique roles in different tissues. 
While we did find serum to play a role in regulating cells responsiveness to GH, we don’t 
fully know what components of the serum are responsible. Serum should be further characterized 
by first conducting an analysis of serums from both fed and fasted fish to see what components 
are different between them. Then the differences could be tested by assessing what effects the 
individual components might have on changing cells responsiveness. Possible initial conditates 
for differences in the serum would be insulin and IGF, as nutritional state changes is known to 
change levels of these (Gomez-Requeni et al., 2005; Norbeck et al., 2007) and both are important 
factors in the regulation of GH.  The effects of these components on lipolysis were tested in 
collaborative work by our lab (Bergan-Roller et al., 2017). Further insights could be found by 
testing these same components on growth-promoting actions such as IGF expression and GHR 
expression. Taken together these studies will help more fully understand the diverse actions of 
GH. 
The actions of fasting and serum on cell responsiveness to GH also should be tested in 
multiple different tissues. As mentioned earlier, GHRs are differentially expressed and are 
present in every tissue we tested. This suggests many potential targets in which for fasting and 
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serum experiments, such as in muscle, gill and adipose tissues. Muscle would be of interest due 
to its large role in organismal growth. Gill and adipose tissue on the other hand would provide 
interesting potential studies with their roles in osmoregulation and lipolysis respectively, which 
are both promoted by GH.  
It is known that the actions of GH are regulated on many different levels. Additional 
research studying different endpoints further downstream of IGF, including IGFBPs and IGFRs 
would allow deeper understanding of the multiple actions of GH. Nutritional state effects both 
IGFBP (Clemmons and Underwood, 1991; Lee et al., 1997) and IGFR levels (Norbeck et al., 
2007) but it is not known how these factors respond to GH in both fed and fasted fish. If 
differences were found we could study the effects of serum and different serum components such 
as insulin and IGF in this switch. In addition to known genes, RNA sequencing could be used to 
generate more potential targets that are differential expressed during fasting. Obviously much 
work is still needed to fully understand even the full growth promoting actions of GH and their 
changes due to nutritional state, as well as the complex multilevel regulation of GH actions. 
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